Podcasts about young investigator award

On this episode of the AMSSM Sports Medcast (X: @TheAMSSM), host Dr. Jeremy Schroeder, DO (X: @thejschro), is joined by two guests to discuss their award-winning research from last year's AMSSM Annual Meeting in Baltimore, MD. First, Dr. Meredith Ehn – the 2024 Young Investigator Award winner – discusses “The NICA Injury Surveillance System: Results from Five Years of Student-Athlete Injury Data,” which was recently published in Research in Sports Medicine. Then, Dr. Rajiv Jain – the 2024 NCAA Research Award winner – shares information about his study, “Assessment Of Stimulated Blink Reflex And Symptoms Over Time In Collegiate Athletes With Sport-related Concussion,” which appeared in Medicine & Science in Sports & Exercise.   Links to the Research Articles: The NICA Injury Surveillance System: Results from Five Years of Student-Athlete Injury Data https://www.tandfonline.com/doi/full/10.1080/15438627.2025.2478399 Assessment Of Stimulated Blink Reflex And Symptoms Over Time In Collegiate Athletes With Sport-related Concussion: https://journals.lww.com/acsm-msse/fulltext/2024/10001/assessment_of_stimulated_blink_reflex_and_symptoms.2413.aspx

Stefano Abbate, profesor de Filosofía Política en la Universitat Abat Oliba CEU, participa activamente en medios y espacios de pensamiento crítico. Destaca por su labor divulgativa como fundador del canal Peregrinos en Distopía y por sus publicaciones sobre gnosis, transhumanismo, sexualidad y orden político. Ha sido premiado por las Academias Pontificias de Teología y recibió el "Young Investigator Award" en 2024.Canal de Stefano - Peregrinos en Distopía: https://www.youtube.com/@PeregrinosenDistopiaEscúchanos también en:Spotify: https://open.spotify.com/show/1HI8XcuaPlOOvaMyuIoQPR?si=i58ihoeAQC6mE0QN6oTP6wApple Podcasts: https://podcasts.apple.com/es/podcast/a-la-de-tr3s/id1548687501iVoox: https://go.ivoox.com/sq/1199920Sigue a Stefano Abbate:Instagram: instagram.com/peregrinosendistopiaTelegram: t.me/PeregrinosenDistopiaTiktok: tiktok.com/@peregrinosendistopiaSpotify: https://open.spotify.com/show/5iLkO3I9xGeY462c8OsLQw?si=be4c81eae74f43a2Sigue a Aladetres:Instagram: https://www.instagram.com/aladetres.esTwitter: https://twitter.com/aladetres_esTiktok: https://www.tiktok.com/@aladetres.esFacebook: https://www.facebook.com/aladetres.esSigue a Lluís Gracia:Instagram: https://www.instagram.com/lluis_graciaTwitter: https://twitter.com/lgraciamolinsContacto: alade3podcast@gmail.comDeja tu like y tu comentario, ¡y no olvides suscribirte y darle a la campanita! :)#aladetres

Send us a textIn this conversation, Dr. Paul Offit and pediatrician Jessica Hochman discuss the importance of vaccinations, the challenges of vaccine hesitancy among parents, and the need for nuanced conversations in public health. They explore the impact of the COVID-19 pandemic on public trust, and the science behind vaccination schedules. The discussion emphasizes the importance of understanding parental concerns while advocating for the safety and efficacy of vaccines. About Paul A. Offit, MD!Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania.Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines.He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal.Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and he was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health.In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, he received the Humanitarian of the Year Award from the BiologicDr Jessica Hochman is a board certified pediatrician, mom to three children, and she is very passionate about the health and well being of children. Most of her educational videos are targeted towards general pediatric topics and presented in an easy to understand manner. For more content from Dr Jessica Hochman:Instagram: @AskDrJessicaYouTube channel: Ask Dr JessicaWebsite: www.askdrjessicamd.com-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA Do you have a future topic you'd like Dr Jessica Hochman to discuss? Email Dr Jessica Hochman askdrjessicamd@gmail.com.The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditions or formulate treatment plans for specific individuals. If you have a concern about your child's health, be sure to call your child's health care provider.

How can neuroscience help us personalise mental health diagnoses and treatments? How are mental heath stats changing and why? How effective are life style changes as a prevention? What other new treatments are proving promising and effective? In this episode we're going to get an update on all the recent research from neuroscience that's studying mental health, and not just the issues and the treatments being used to deal with them, but also the importance of the brain itself in the perception of our mental health, and the lifestyle choices that can preventatively ward off the issues before they arise; things like nutrition, sleep, exercise, and social contact. We'll be looking at the big one: depression and its connection to inflammation, and a wide range of buzz therapies including psychedelic therapy and cold water immersion. Today's guest has just written a book for the public on this topic “The Balanced Brain: The science of mental health”, and her lab at MRC Cognition and Brain Sciences in Cambridge bridges the gap between the nuts and bolts of cognitive neuroscience and the more mind base of clinical psychology. She is neuroscientist and author Camilla Nord. In 2022, she was named a Rising Star by the US Association for Psychological Science, and received the Young Investigator Award from the European Society for Affective and Cognitive Science.   Now it strikes me that if we can integrate new evidence from brain research into the clinical psychology field, we‘ve got a much better shot at treating ever rising numbers of mental health diagnoses and perhaps educating a good portion of the next generation enough to avoid these issues all together. It may be a pipe dream but we've got to try. What we discuss:  00:00 Intro 07:00 Our perception of pain. 11:00 Body changes lead to mental health changes. 12:00 Our ‘Inside-out' perception is an active predictor of our mental health and the outside world. 16:00 The importance of narrative repetition to our self-perception. 18:00 Individualised data and solutions to mental health are impractical for our one-size-fits-all medical systems on a budget. 23:30 Nutritional Psychiatry - the connection between diet and mental health. 26:30 Gut-brain axis importance. 28:00 The risk of dieting affecting pleasure centres and thus motivation and mental health. 30:00 Inflammatory diet choices and lifestyle leading to depression. 33:30 Microbiome research: promise vs wishful thinking. 37:45 Social connection, nature connection and connection to meaning. 40:45 Some mental health symptoms can be useful and adaptive. 43:20 Sport and physical exercise to improve mental health. 46:00 Depression leads to a lack of drive to obtain pleasure - Anhedonia. 48:20 Sleep neuroscience. 53:30 Anger management and ‘hangriness'. 56:20 The Placebo effect is a useful part of a treatment's effect. 58:00 Changing diagnosis rates in mental health. 01:02:00 Psychedelic therapy was unpopular before the last 10 years of study. 01:06:00 MDMA's uses for PTSD, and modifying beliefs and expectations. 01:08:10 Connection between psychosis and cannabis. 01:09:20 Cannabis CBD Oil treatment of THC addiction. 01:11:15 Cold water immersion for euphoria and pain tolerance. 01:13:00 The changing nature of mental health. References: Camilla Nord, “The Balanced Brain, the Science of mental health”. Felicity Jacka, Nutritional psychiatry, Guardian Article Metabolic health influences learning paper. Clinical psychosis vs mediumship paper. Connection to symptoms changes mental health outcomes. Oliver J Robinson - Adaptive anxiety paper Wim Hof, Cold water Immersion method, list of science papers

In this episode of The Thyroid Answers Podcast, I discuss Thyroid lab tests, lab values, and the over-prescription of thyroid medication. Topics covered in this episode include:  Optimal vs Lab reference ranges Lab value vs lab interpretation The problem with optimal ranges Seasonal variability and other factors that influence TSH The over-prescription of thyroid medication and More...   Dr. Joe El-Khoury is Associate Professor of Laboratory Medicine at Yale School of Medicine and Director of the Clinical Chemistry Laboratory and fellowship program at Yale-New Haven Health. He is board-certified by the American Board of Clinical Chemistry and a fellow of the Association for Diagnostics and Laboratory Medicine Academy. He currently serves on the Editorial Boards of Clinical Chemistry and Clinical Biochemistry, as Chair of the IFCC Committee on Kidney Diseases, and on the Board of Directors for ADLM. He is the recipient of the 2023 Young Investigator Award from the International Federation for Clinical Chemistry and Laboratory Medicine. He recently launched his own YouTube channel, entitled “Clinical Chemistry with Joe El-Khoury”, which infuses science with comedy and is focused on improving laboratory medicine practice. https://www.youtube.com/@UCYuD1s42xkXSd70QSLRB6ew

Summary Dr Jenny Murphy, is a senior lecturer at the University of Surrey. Here she discusses interoception and its importance in mental and physical health. Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications include interoception training for anxiety and physical health conditions. Jenny discusses the role of perception and external cues in regulating the body, as well as the potential factors influencing interoception. She explains that her research focuses on measuring interoception and its development, and she is currently studying interoception across the menstrual cycle. Jenny also discusses the clinical implications of her work and the possible integration of interoception into therapy. She emphasizes the importance of interdisciplinary collaboration and the need for more research on the relationship between thoughts, feelings, and behavior. Jenny mentions her upcoming textbook on interoception and concludes by offering advice on improving well-being through the understanding and regulation of interoceptive signals. She is editing a textbook on interoception at the moment that should be published by Springer, Nature at the end of the year. Keywords interoception, signals, perception, attention, evaluation, mental health, physical health, measurement, clinical applications, perception, external cues, regulation, body, interoception, development, menstrual cycle, clinical implications, therapy, interdisciplinary collaboration, thoughts, feelings, behavior, textbook, well-being Takeaways Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications of interoception include training for anxiety and physical health conditions. Perception and external cues play a role in regulating the body and compensating for imperfect interoceptive signals. Jenny's research focuses on measuring interoception and its development, with current studies on interoception across the menstrual cycle. There are limited clinical implications of interoception research at present, but it may contribute to therapies like mindfulness and cognitive-behavioral therapy. Interoception is an interdisciplinary field that can benefit from collaboration and integration with other areas of research. The relationship between thoughts, feelings, and behavior is complex and requires further investigation in the context of interoception. Jenny is working on a textbook on interoception that aims to provide an up-to-date and comprehensive resource for students and practitioners. Improving well-being through interoception involves recognizing the balance between paying attention to bodily signals and focusing on external cues. Publications https://www.jennymurphylab.com/publications Bio Jenny completed her PhD at King's College London in December 2019. Here she investigated the measurement of interoception, it's developmental trajectory and the relationship between interoception, health and higher order cognition. In April 2020 she took up a lectureship position at Royal Holloway University of London and in March 2024 she took up a senior lectureship position at the University of Surrey. Jenny's work on interoception has been recognised by several awards for doctoral contributions (from the British Psychological Society, Experimental Psychology Society and King's College London) and early career prizes (the American Psychological Society Rising Star Award and the Young Investigator Award from the European Society for Cognitive and Affective Neuroscience). Jenny is particularly interested in sex differences in interoceptive abilities, including how these emerge across development and whether they relate to sex differences in mental and physical health. She currently holds a New Investigator Grant from the Medical Research Council for investigating changes in interoception across the menstrual cycle.

Summary Dr Jenny Murphy is a senior lecturer at the University of Surrey. Here she discusses interoception and its importance in mental and physical health. Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications include interoception training for anxiety and physical health conditions. Jenny discusses the role of perception and external cues in regulating the body, as well as the potential factors influencing interoception. She explains that her research focuses on measuring interoception and its development, and she is currently studying interoception across the menstrual cycle. Jenny also discusses the clinical implications of her work and the possible integration of interoception into therapy. She emphasizes the importance of interdisciplinary collaboration and the need for more research on the relationship between thoughts, feelings, and behavior. Jenny mentions her upcoming textbook on interoception and concludes by offering advice on improving well-being through the understanding and regulation of interoceptive signals. She is editing a textbook on interoception at the moment that should be published by Springer, Nature at the end of the year. Keywords interoception, signals, perception, attention, evaluation, mental health, physical health, measurement, clinical applications, perception, external cues, regulation, body, interoception, development, menstrual cycle, clinical implications, therapy, interdisciplinary collaboration, thoughts, feelings, behavior, textbook, well-being Takeaways Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications of interoception include training for anxiety and physical health conditions. Perception and external cues play a role in regulating the body and compensating for imperfect interoceptive signals. Jenny's research focuses on measuring interoception and its development, with current studies on interoception across the menstrual cycle. There are limited clinical implications of interoception research at present, but it may contribute to therapies like mindfulness and cognitive-behavioral therapy. Interoception is an interdisciplinary field that can benefit from collaboration and integration with other areas of research. The relationship between thoughts, feelings, and behavior is complex and requires further investigation in the context of interoception. Jenny is working on a textbook on interoception that aims to provide an up-to-date and comprehensive resource for students and practitioners. Improving well-being through interoception involves recognizing the balance between paying attention to bodily signals and focusing on external cues. Publications https://www.jennymurphylab.com/publications Bio Jenny completed her PhD at King's College London in December 2019. Here she investigated the measurement of interoception, it's developmental trajectory and the relationship between interoception, health and higher order cognition. In April 2020 she took up a lectureship position at Royal Holloway University of London and in March 2024 she took up a senior lectureship position at the University of Surrey. Jenny's work on interoception has been recognised by several awards for doctoral contributions (from the British Psychological Society, Experimental Psychology Society and King's College London) and early career prizes (the American Psychological Society Rising Star Award and the Young Investigator Award from the European Society for Cognitive and Affective Neuroscience). Jenny is particularly interested in sex differences in interoceptive abilities, including how these emerge across development and whether they relate to sex differences in mental and physical health. She currently holds a New Investigator Grant from the Medical Research Council for investigating changes in interoception across the menstrual cycle.

The Walter A. Shaw Young Investigator Award in Lipid Research recognizes outstanding research contributions in the area of lipids by a young investigator. Judith Simcox is an assistant professor of biochemistry at the University of Wisconsin–Madison. Her lab studies plasma lipids that regulate metabolic disease and explores how these lipids function using lipidomics, genetics, and cellular and molecular biology techniques. Learn more: https://www.asbmb.org/asbmb-today/people/081623/asbmb-names-2024-award-winners.

The ASBMB Mildred Cohn Young Investigator Award recognizes outstanding research contributions to biochemistry and molecular biology. Nozomi Ando is an associate professor at Cornell University's chemistry and chemical biology department. Her lab works on new structural biology methods, such as diffuse scattering analysis of X-ray diffraction images of protein crystals to obtain information about movement within proteins. Learn more: https://www.asbmb.org/asbmb-today/people/081623/asbmb-names-2024-award-winners.

EPISODE SUMMARY Join scientist and mindset & high-performance coach Claudia Garbutt and accomplished aging researcher José Pedro Castro, PhD, as they discuss aging and health In this episode, we talk about: - What is aging & age-related inflammation - Good inflammation VS bad inflammation - Aging clocks and important biomarkers     Episode NOTES José Pedro Castro completed his PhD in Biomedicine in 2015 by Universidade do Porto Faculdade de Medicina. He then moved to the German Institute of Human Nutrition and joined the Grune Lab (Berlin, Germany) to study how age-related redox and metabolism changes impact the adipose tissue and skeletal muscle.  After completing his aims, he was awarded with the prestigious DFG Max-Kade fellowship and moved to Harvard Medical School (Boston, USA) where he joined the Gladyshev Lab. There, he explored the genetics of aging, age-related diseases and lifespan control from a systems biology perspective.  Recently, and after returning to Portugal, he has joined Logarinho Lab at I3S (Porto, Portugal) after being awarded with the FCT CEEC 5th Edition for Assistant Researcher. Published over 30 articles in peer-reviewed journals such as Cell, Nature Aging or Science Advances. Has received several awards and/or honors, including Early Research Career Award (2010) and Young Investigator Award (2013). He is a reviewer for several scientific journals and a review editor for Redox Biology and Frontiers in Aging. His focus lies on understanding the biology of aging and age-related diseases. Using a combination of experimental and computational approaches he is keen to unravel age-related molecular trajectories leading to chronic diseases.  He is also an assistant professor for Immunology and an invited professor for Biogerontology and Aging and Nutrition. He is involved in several dissemination activities such as the creation of the Portuguese Society for Science and Medicine of Longevity.  On a more personal note, José also dedicates his time to literature by reading as much as he can and writing short fiction stories, but his true desire is to one day write a full novel!   Links: https://www.linkedin.com/in/jos%C3%A9-pedro-castro-phd-92528620   ------------ Click this link to listen on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess   Help me keep this show running and awesome: Hit subscribe and join the tribe! THANK YOU for your support! 

In this episode Chris talks to Gláucia Murta, a postdoc in ML4Q, who was won the cluster's Young Investigator Award. They talk about Gláucia's passion for fundamental questions, device independence and a great outreach project, the podcast O Q Quantico she just launched in her home country, Brazil.

Fan Yang, PhD is an Associate Professor at Stanford University with joint appointments in the Departments of Orthopaedic Surgery and Bioengineering joins OsteoBites to discuss her work on tissue engineering strategies for elucidating OS biology and drug discovery.Fan Yang, PhD is the founder and Director of Stanford Stem Cells and Biomaterials Engineering Laboratory, and also Co-director of Stanford NIH Biotechnology Training Program. Her research seeks to develop hydrogels with unique micro- and nano- scale properties to promote stem cell differentiation, tissue regeneration and immunomodulation, with a focus on musculoskeletal diseases. Her lab also harnesses biomaterials to create 3D cancer models with in vivo-mimicking phenotype and drug responses. Such 3D models could enable discovering novel druggable targets that would otherwise be missed using conventional 2D culture, and enable high-throughput drug screening with reduced cost and time than animal models. Prior to joining Stanford, Dr. Yang received her Ph.D. in Biomedical Engineering from Johns Hopkins University, and then completed a postdoctoral fellowship at MIT under Prof. Robert Langer. In recognition of her innovation, she has been recognized by numerous awards including Fellow of American Institute for Medical and Biological Engineering, MIT TR35 Global list honoree, National Science Foundation CAREER award, Young Investigator Award from Society for Biomaterials, Biomaterials Science Lectureship Award, Young Investigator award from Alliance for Cancer and Gene Therapy, Ellen Weaver Award by the Association for Women in Science, Baxter Faculty Scholar Award, the McCormick Faculty Award, Stanford Asian American Faculty Award, and the Basil O'Connor Starter Scholar Research Award, etc.

Welcome to the Derm Club Podcast, where I recently had the pleasure of hosting Dr. William Damsky, a leading figure in cutaneous sarcoidosis. In this session, Dr. Damsky, from Yale New Haven Hospital and a recipient of the American Academy of Dermatology's Young Investigator Award, shares his extensive knowledge on sarcoidosis. We dive into what cutaneous sarcoidosis is, its causes, and risk factors like genetics and environmental exposures. Dr. Damsky also sheds light on the intriguing roles of epigenetics and occupational factors in sarcoidosis. Join us for this insightful conversation exploring the complexities and current treatments of this multifaceted autoimmune disease. Please SUBSCRIBE to the Derm Club Podcast wherever you like to listen whether on YouTube, Apple, or Spotify. Together, let's explore the fascinating secrets of dermatology and skincare. Connect with me across Social: Twitter: https://twitter.com/drhankopelman Instagram: https://www.instagram.com/doctor.han/ TikTok: https://www.tiktok.com/@drhankopelman Blog: https://www.hannahkopelman.com/blog/ The content of this podcast is for entertainment and educational purposes only. This content is not meant to be a substitute for medical advice or treatment for any medical condition. --- Send in a voice message: https://podcasters.spotify.com/pod/show/hannah-kopelman/message

In this episode, we welcome Amisha Parekh de Campos, PhD, MPH, RN, CHPN to the show where she speaks on the research that she is conducting surrounding people of color in end-of-life care. Amisha speaks on the importance of incorporating race into practice to best serve our minority populations and how we can advocate for our patients of color.    About Amisha: Amisha Parekh de Campos, PhD, MPH, RN, CHPN has a joint appointment as an Assistant Clinical Professor, University of Connecticut School of Nursing, and Quality and Education Coordinator of the Middlesex Health Hospice Program, Middletown, CT. Amisha received her PhD in Nursing from the University of Connecticut (2020), and BS and MPH in Global Health from George Washington University (2001 & 2005). She received her BSN from the University of St. Joseph in 2009; additional certifications include hospice and palliative care (CHPN). Amisha started her career in public health by establishing public health clinics and training community health workers in rural areas of south India and the Dominican Republic. She led initiatives on the prevention of HIV, tuberculosis, and mosquito-borne illnesses with community, government, and private organizations. For the past ten years, Amisha has worked in hospice home care in various leadership roles, including community liaison and clinical supervisor. Currently, she manages research, quality, education, and orientation for the Hospice Homecare program, which serves approximately 150,000 people in Connecticut. In addition, Amisha is an Assistant Clinical Professor at the University of Connecticut, School of Nursing working towards enhancing the palliative care curriculum and education among undergraduate students. She is a Robert Wood Johnson, Future of Nursing Scholar (2017-2020) and Jonas Scholar for Chronic Health (2017-2020). In 2019, Amisha received the 2019 Hospice and Palliative Nurses Foundation Scholarship to fund a study in advance care planning through simulation with registered nurses. She is the 2021 recipient of the Hospice and Palliative Credentialing Center Certified Hospice and Palliative Nurse of the Year and recipient of the 2021 Young Investigator Award from the Connecticut Coalition to Improve End-of-Life Care. Amisha was also featured in the Journal of Hospice and Palliative Nursing. Amisha's program of research focuses on end-of-life care communication. Her dissertation focused on simulation among registered nurses in advance care planning communication. Working at a community health system, she has noticed the disparities in end-of-life care among people of color. With her public health background and working with communities, she would like to assess the barriers and facilitators to end-of-life care and provide interventions to expand EOL services to this population.      

This week, Rachel chats with Oriel FeldmanHall,  Professor of Cognitive, Linguistics, and Psychological Sciences at Brown University. Oriel's lab leverages methods from behavioral economics, social psychology, and neuroscience to explore the neural bases of social behavior, and the role of emotion in shaping social interactions. She has won numerous awards, including the Cognitive Neuroscience Society's Young Investigator Award for outstanding contributions to science, the Association for Psychological Science's Janet Taylor Spence Award for Transformative Early Career Contributions, and the American Psychological Association's Distinguished Scientific Award for Early Career Contribution to Psychology. In this episode, Oriel provides an introduction to the world of affective science, explaining how her team measures and studies emotion. She describes how the emotions that we expect to feel—and the inaccuracies in our predictions—shape our judgments and behavior, and the complex relationship between emotion and depression. We also discuss the hazards of sharing scientific findings on twitter, and how some of the best research questions originate in coffee shops.  JOIN OUR SUBSTACK! Stay up-to-date with the podcast and become part of the ever-growing community

Dr. Alexis “Lekki” Wood is Associate Professor at USDA/ARS Children's Nutrition Research Center in the Division of Pediatrics-Nutrition at Baylor College of Medicine. Research in Lekki's lab aims to better understand how food influences our health. She examines the full chain of changes that occur from the moment food is put into our mouths, trough digestion and absorption of particular molecules, to where those molecules go and how they affect our organs. Outside of work, you can find Lekki working out at the gym and spending quality time with her two children and their German shepherd. She is also a Lego builder and a competitive Pokemon card player along with her son. She received her BSc with honors in Psychology and from the University of Warwick. Afterwards, she completed her Postgraduate Certificate in Education at the University of Cambridge. Lekki enrolled in graduate school at King's College London where she earned her MSc in social, genetic, and developmental psychiatry and her PhD in statistical genetics. Next, she conducted postdoctoral research at the University of Alabama focusing on statistical genetics and epidemiology. Lekki served on the faculty at The University of Texas, Health Sciences Center for about two years before joining the faculty at Baylor College of Medicine where she is today. Lekki has received a variety of awards and honors for her work, including the Young Investigator Award from the International Congress on ADHD and the Young Investigator Award from the Department of Pediatrics at Baylor College of Medicine. In addition, she has received the Scott Grundy Award for Excellence in Metabolism Research and the Mark Bieber Award for Excellence in Nutrition Research, both from the American Heart Association. She was also named a Fellow of the American Heart Association in 2015. In our interview, she shares more about her life and science.

Dr. Staci Leisman is a board certified internist and nephrologist who practices nephrology at Mount Sinai Hospital. She is also an accomplished educator in the Icahn School of Medicine at Mount Sinai. 
Dr. Leisman received her B.A. in English Language and Literature from Yale University, where she graduated magna cum laude and was inducted into Phi Beta Kappa. She received her M.D. from Washington University in St Louis, where she was one of 8 recipients of the Distinguished Scholar Award. She completed her residency in Internal Medicine and fellowship in Nephrology at Mount Sinai Medical Center. As a fellow, she completed research in transplant immunology in the laboratory of Dr. Peter Heeger, which resulted in a Young Investigator Award from the American Society of Transplantation and two oral presentations at the American Transplant Congress. During her fellowship, she co-first authored and was a contributing author on numerous papers. 
Dr. Leisman's clinical duties include caring for patients on dialysis at an outpatient dialysis facility, as well as attending on the inpatient renal service at Mount Sinai Hospital. 
Dr. Leisman has been extensively involved in teaching throughout her career. She currently teaches students at all levels of medical education, including medical students, residents and fellows.  She is the course director for the Human Physiology course in the medical school, and holds a secondary appointment in the Department of Medical Education, where she is a co-director for the medical school curriculum. In her capacity as an educator, she has won numerous awards including Teacher of the Year at North General Hospital, the Edward Ronan Student Council Award at the Icahn School of Medicine, the Institute for Medical Education's Excellence in Teaching Award, the Student Council Lifetime Achievement Award, the JOWMA Outstanding Achievement Award, and the Gold Humanism in Medicine Award. She has been selected for membership in the Institute for Medical Education as a Master Educator. 
Dr. Leisman also serves on the International Association of Medical Science Educators' educational scholarship committee, and serves on the editorial board of Advances in Chronic Kidney Disease, the Journal of the National Kidney Foundation. She is the Deputy Education Director for the Kidney Self Assessment Program (KSAP), the preeminent board preparation tool published by the American Society of Nephrology. _______________________________________________________ Become a JOWMA Member! www.jowma.org  Follow us on Instagram! www.instagram.com/JOWMA_org  Follow us on Twitter! www.twitter.com/JOWMA_med  Follow us on Facebook! https://www.facebook.com/JOWMAorg/ Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

Dr. Weizhe Hong is a Professor of Neurobiology, Biological Chemistry, and Bioengineering at the University of California Los Angeles. His research aims to uncover the fundamental neural mechanisms underlying social behavior, with a specific focus on empathy and prosociality. Dr. Hong earned his Ph.D. degree in 2012 from Stanford University and was a Helen Hay Whitney Postdoctoral Fellow at the California Institute of Technology during 2012-2015. In 2016, he joined UCLA as Assistant Professor, and he was promoted to Associate Professor with tenure in 2020 and to Full Professor in 2023. He is also the recipient of a Young Investigator Award from the Society for Neuroscience, an Early Career Award from the Society for Social Neuroscience, a Mallinckrodt Scholar Award, a Vallee Scholar Award, a Searle Scholar Award, a Packard Fellowship in Science and Engineering, a McKnight Scholar Award, a Klingenstein-Simons Fellowship, and a Sloan Research Fellowship.​Link: A Multi-Brain Framework for Social InteractionLink: Neural Basis of Prosocial Behavior

What does the journey look like to evolve from an expert presenter to a sought-after speaker and thought leader? How can you escape what I call “the expert trap” and make the shift into thought leadership? My guest and Thought Leader Academy graduate, Teri DeLucca, PhD, has done exactly this. I know you'll be inspired by Teri! In this episode, Teri and I talk about: Why she started her business a few years ago Her initial reluctance to share personal stories and be vulnerable - and what changed her mind Her desire to escape “the expert trap” and go beyond her comfort zone of academic presentations The impact storytelling and vulnerability has had on her, her business, her customers, and her audiences Why she joined the Thought Leader Academy and what she got out of it The elements we've worked on together to create her signature talk, from incorporating humor and video clips to coming up with an acronym and planting sales seeds for her offer About My Guest: Dr. Teri DeLucca is the Founder and CEO of Impact Early Education, a professional development institute for the preschool industry. She completed a dual PhD in developmental psychology and educational psychology from the University of Florida where her research focused on the cognitive, social, and academic development of children. She previously worked as a research scientist for a children's early literacy intervention program and then accepted an applied position as Vice President of Operations for a system of preschools and extended day programs. Her work has been recognized by multiple awards including the Sigma Xi Women in Science Award, Academic Pediatric Association's Young Investigator Award, the Institute of Education Sciences Randomized Trials Award, and most recently she was recognized as one of the Top 40 Under 40 Business Leaders locally. Dr. DeLucca is a member of the John Maxwell Leadership Team and is a John Maxwell certified speaker. She is also a graduate and certified speaker through the Speaking Your Brand Thought Leader Academy. Dr. DeLucca just completed her Presidency with The Junior Service League of St. Augustine, which is a local women's volunteer organization. She enjoys serving the community both locally and abroad and her favorite volunteer endeavors are serving at a children's home in Guatemala for several years and serving with the Big Brothers Big Sisters program. She has been matched with her “Little” sister Hannah for 18 years now! Above all else, the most important role she has is that of mom to two wonderfully amazing boys, who never let her take life too seriously.  About Us: The Speaking Your Brand podcast is hosted by Carol Cox. At Speaking Your Brand, we help women entrepreneurs and professionals clarify their brand message and story, create their signature talks, and develop their thought leadership platforms. Our mission is to get more women in positions of influence and power because it's through women's stories, voices, and visibility that we challenge the status quo and change existing systems. Check out our coaching programs at https://www.speakingyourbrand.com.  Links: Show notes at https://www.speakingyourbrand.com/338/ Teri's website: https://impactearlyed.com/ Discover your Speaker Archetype by taking our free quiz at https://www.speakingyourbrand.com/quiz/ Enroll in our Thought Leader Academy: https://www.speakingyourbrand.com/academy/    Connect on LinkedIn: Carol Cox = https://www.linkedin.com/in/carolcox Teri DeLucca = https://www.linkedin.com/in/teri-delucca-ph-d-46b296200/  Related Podcast Episodes: Episode 241: The Expert Trap: What Holds Women Back from Thought Leadership with Carol Cox Episode 327: From Expert to Thought Leader: 3 Key Strategies You Need Now to Set Yourself Apart in Our New AI-Driven World with Carol Cox Episode 307: From University Lecturer to Thought Leader with Heather Hausenblas, PhD  

The Young Investigator Award Winners. Danesh Kella, MBBS, FHRS and Jason T. Jacobson, MD, FHRS congratulate the Heart Rhythm 2023 Young Investigator Award winners. This episode was recorded live at Heart Rhythm 2023 in New Orleans, Louisiana. https://www.hrsonline.org/education/TheLead Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stock Ownership: Atlas 5D D. Kella: No relevant financial relationships with ineligible companies to disclose.

Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania. Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq®, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. Read Dr. Offit's complete bio here: https://www.chop.edu/doctors/offit-paul-a _______________________________________________________ JOWMA Podcast | Ep. 1 How to Fool Yourself Less Often: Medical Decision Making for Regular People https://anchor.fm/jowma/episodes/Ep--1-How-to-Fool-Yourself-Less-Often-Medical-Decision-Making-for-Regular-People-eav2pu _______________________________________________________ Become a JOWMA Member! www.jowma.org  Follow us on Instagram! www.instagram.com/JOWMA_org  Follow us on Twitter! www.twitter.com/JOWMA_med  Follow us on Facebook! https://www.facebook.com/JOWMAorg/ Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

Bonnie Ky, MD, MSCE, FACC and Megan Mulholland, MSc, the 2022 JACC: CardioOncology Young Author Achievement Award winner, discuss science and training in the field, career goals and plans, and her original research manuscript on immune therapy and atherosclerosis now online in JACC: CardioOncology.

Join A Cure in Sight to discuss systemic therapies for metastatic uveal melanoma with Dr. Meredith McKean.   We discuss when to use systemic therapies, what is out there besides KIMMTRAK, how to determine a path forward for introducing systemic therapies in metastatic management   McKean received her bachelor's degree from Iowa State University, where the promising athlete ran cross-country and track. During fellowship, McKean studied biomarkers for response to immune checkpoint inhibitors (ICI) in metastatic melanoma, earning her an American Society of Clinical Oncology 2017 Young Investigator Award. She now serves as the director for the Melanoma and Skin Cancer Research Program at the Sarah Cannon Research Institute at Tennessee Oncology.   ANNOUNCEMENTS: Head to our site to register for a 5K Lookin' for a Cure near you! www.lookinforacure.org   Swing for Sight April 22, 2023 REGISTER for SWING FOR SIGHT TODAY: Subscribe to the newsletter to stay in the know Newsletter link   Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org  The Eye Believe Podcast is brought to you by Castle Biosciences. Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.  This podcast was hosted by Danet Peterson and produced by Page Fronczek.

Dr. Alexander Whiting is a neurosurgeon and director of epilepsy surgery for Allegheny Health Network's Neuroscience Institute. He specializes in state-of-the-art epilepsy treatments, including stereoelectroencephalography (SEEG), seizure focus resections, laser ablations, vagal nerve stimulation, and responsive neurostimulation. Additionally, he has clinical interests in complex spine and brain disorders, and offers a range of surgical options and interventions for these conditions. Dr. Whiting completed his residency at the Barrow Neurological Institute in Phoenix, Arizona. He completed his fellowship in epilepsy surgery at the Cleveland Clinic in Cleveland, Ohio, and was awarded the American Epilepsy Society's prestigious Young Investigator Award. Today we speak to Dr. Whiting about SEEG.

Dr. Melik Demirel is a Professor of Engineering Science and Mechanics at The Pennsylvania State University. Melik is fascinated by complexity in living and nonliving systems. He works at the intersection of biology, materials science, and computational science to understand whether patterns in living and nonliving systems follow mathematical and statistical rules, to determine the underlying physical basis of these patterns, and identify relevant mechanisms. He likes listening to music to engage the creative aspects of his mind. Some of his favorites are composers like Beethoven and Rachmaninov. Melik's wife plays piano, and his son plays piano and cello, so music is a big part of their lives. Malik received is B.S. and M.S. in Engineering from Boğaziçi University in Turkey and was awarded his PhD in Materials Science and Engineering from Carnegie Mellon University. Afterwards, Melik conducted postdoctoral research at Los Alamos National Laboratory and was awarded an Alexander von Humboldt Fellowship in Molecular Biology at the Max Planck Institute in Gottingen, Germany. He accepted a faculty position at Penn State in 2003. Melik was a recipient of the Young Investigator Award from the Office of Naval Research within the Department of Defense, was selected as a Wyss Institute Visiting Scholar at Harvard University, and was awarded the Outstanding Research Award from Penn State, among other honors during his career. In this episode, he tells us about his experiences in life and science.

Dr. Charles Ryan, president and CEO of the Prostate Cancer Foundation (PCF), joins ASCO Daily News Editor-in-Chief Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute, to assess impactful prostate cancer research from the PCF's recent conference and discuss Dr. Ryan's vision for the future, including increasing access to cutting-edge care. TRANSCRIPT Dr. Neeraj Agarwal: Welcome, to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the editor-in-chief of the ASCO Daily News, and director of the Genitourinary Cancers Program at the University of Utah Huntsman Cancer Institute. Today, we'll be discussing compelling research that was featured at the recent Prostate Cancer Foundation Scientific Retreat, and I'm very pleased to welcome Dr. Charles Ryan, the president, and CEO of the Prostate Cancer Foundation. Our full disclosures are available on the transcript of this episode, and disclosures relating to all episodes of the ASCO Daily News Podcast are available on our transcripts at: asco.org/podcasts. Dr. Ryan, thank you for taking the time to be with us today. Dr. Charles Ryan: Dr. Agarwal, thank you. It's my pleasure to be with you. Dr. Neeraj Agarwal: So, Dr. Ryan, before I discuss the PCF meeting, I would like to ask you, what made you move to the PCF as the president and CEO when you had a flourishing career as a division chief of a large academic program, and as one of the top and internationally recognized investigators in prostate cancer? Dr. Charles Ryan: Well, thanks. That's a fair question, I guess. And it took me about three minutes to make the decision when I was offered the position, simply because the Prostate Cancer Foundation has been one of my intellectual homes for my entire career. I've been at the University of Wisconsin, Memorial Sloan Kettering Cancer Center, UCSF, and the University of Minnesota, and all those institutions were affected by the Prostate Cancer Foundation, or previously, CaP CURE. So, I was involved in their research during my time at all those institutions. In addition to my own personal legacy with the PCF, but more importantly, is the fact that it is an organization that funds the deepest scientific inquiry into prostate cancer and the ways that it can cause suffering and death for men with the disease and has made tremendous progress in identifying factors that lead to that lethality. It's also a community of scholars, a community of researchers, that is a platform really for collaboration. And it's also an organization with a world reach - we fund research in 28 countries around the world, and we fund research going from the scope of very basic research to correlative research, to quality of life, and health services research. Dr. Neeraj Agarwal: That is truly impressive and inspiring. So, what is the mission of the Prostate Cancer Foundation formally? Dr. Charles Ryan: Formally, it's pretty simple. The mission of the Prostate Cancer Foundation is to reduce the death and suffering from prostate cancer. Dr. Neeraj Agarwal: So, the 29th PCF Scientific Retreat was recently held on October 27 to October 29th in Carlsbad, California. What were the goals and objectives of this meeting? Dr. Charles Ryan: The meeting, we call it the retreat, it's an annual event and it always has several goals. One is, it's where we announce and hand out, if you will, our awardees of our various awards that we give. It's also a reporting-in process where those who have been using PCF funding are called to come and discuss their work. We also want it to be an open forum for individuals to come and interact - it's really a collaboration and an interaction vehicle as much as anything. So, when you come to our scientific retreat, we all stay at the same hotel, we all share meals together, nobody goes out for dinner. You don't leave the campus, essentially, of the hotel where we are. We have many, many round tables set out, it's designed to be interactive. We have a big room where people are giving their talks, but if you step outside of the room, there are likely to be many, many conversations happening, and those conversations range from collaborations being formed to people looking for jobs, to people getting advice and mentoring, and even people sharing, as I've done over the years, compelling and challenging patient stories around prostate cancer, and really engaging in what communities do - which is, share ideals, share a mission, and share a passion for what they do. Dr. Neeraj Agarwal: Very interesting. Very inspiring. Please tell us some of the highlights of the meeting. Dr. Charles Ryan: Sure. Well, there are many highlights. There are many things happening in prostate cancer research. Most notably, there are a number of papers and investigators that are looking at how prostate cancer evolves, and probably the most significant set of observations that have been made in the field in the last decade, have been understanding the diverse and numerous mechanisms that underlie the evolution of prostate cancer from a disease that responds to hormonal manipulation, to one that becomes resistant to hormonal manipulation. And so, a lot of the work that's happening now is identifying, for example, the evolution of neuroendocrine prostate cancer, or mixed types of prostate cancer, or this sort of evolution of it under constant therapy. And that is allowing the exposure of new targets that we can exploit for new therapy development, and that feeds into some of the grant-making process that's going on in the background. And so, you have a lot of individuals who are looking at this or that mechanism pathway related to disease resistance that they can exploit, and whether they can create small molecules to do that, or antibodies to do that, et cetera. At the same time, we have a strong component of discussion of how prostate cancer affects different populations. So, we had some really nice talks looking at healthcare disparities and different populations across the world, and how they're affected by prostate cancer, and how care delivery may be impacted in those groups of patients. And then you have topics ranging around survivorship and other factors that are looking at what is life like for a man with advanced prostate cancer, which is in many cases, you know, men who get prostate cancer, who have recurrent disease, who end up going on systemic therapy are frequently on the treatment for 5, 10, 15 years. And so, survivorship, and how they live their life, and what the complications are of that treatment, is tremendously important because it's such a daily experience for these men undergoing treatment. Dr. Neeraj Agarwal: So, how does the Prostate Cancer Foundation support and build the next generation of prostate cancer researchers? Dr. Charles Ryan: Right. So, the PCF supports the next generation in a very specific way, in addition to the informal way of bringing people together and inducing collaborations. We have a program called the Young Investigator Program. It started formally in 2008, but before that, there were one-off, if you will, Young Investigator Awards being given. So, our Young Investigator Awardees receive $75,000 per year to support their work, and we awarded 34 of those this year. The range is somewhere from 25 to 34 per year. We get over 100 applications for them every year. It's a straightforward application - they need to have a project that's going to be about three years in length, they need to be mentored, and they are best served by describing a mentorship plan for themselves and how that mentorship relationship will help them grow in their careers. Now, once you become a Young Investigator, it's not that we just write you a check and wish you well, we do that, but we also have annual check-ins. So, we try to visit the sites of our Young Investigators, see them in their home institution, and meet with their colleagues and their mentors. And that's one of the things I do, or Howard Soule does-- Howard Soule, is our chief scientific officer, one of those things we try to do. We also bring them to the scientific retreat that we just had last week, and we have them present their data. So, a vast number of the individuals who are presenting at the scientific retreat are in fact, Young Investigators, or they were Young Investigators when they started the projects that they are presenting. And then, the other thing we do is we have another retreat specifically for the Young Investigators, and that's called the Coffey-Holden Retreat, and that's named after Don Coffey, the late researcher from Johns Hopkins, who is really considered to be one of the grandfathers of prostate cancer research, and Stuart or Skip Holden, who is one of the founders of the Prostate Cancer Foundation, and a urologist at UCLA. So, that event that we do is designed for people to come to give highlights of the work that they're doing; it's designed to be incredibly interactive. In fact, we have 15 or so minutes of presentation, followed by sometimes 25 minutes of questions for each presenter. There's always a line of people who are waiting to ask questions, and it's designed to engage and have that dialogue with the Young Investigators, to make their science better, and to get it known. And so, the Young Investigator Program, it's about 30 individuals per year on average, and the average age is about 30. Many of these are postdoctoral PhDs, and many of them are fellows, or early-stage faculty, MDs. And I like to think that if somebody's going to work until the age of 70, we're stimulating, or launching a 40-year career with these Young Investigator awards. So, I like to think that if we give 25 out, times 40 years, that's 1,000 years of research that we're sort of stimulating with this Young Investigator program. And I bring that up for the reason that we're very proud of the fact that many of our Young Investigators may start out in prostate cancer, and their ideas, their science, takes them elsewhere. And that's what science does. And we, of course, are very, very focused on solving the problem of prostate cancer, and we want people to do that. But we also understand that by launching a scientist, by launching a scientific career, you may end up with people going off in different directions. And so, we have many examples of that. And in my talk this year, I actually highlighted a person who, let's say she won an investigator award when she was young, it was before the formal Young Investigator Award was named, and this was a person who is creating conjugates for the delivery of chemotherapy to prostate cancer cells. And this was Carolyn Bertozzi up at UC Berkeley, and she just won the Nobel Prize. She didn't win the Nobel Prize for research she did on prostate cancer, but at some point, at one point in her career, this was a direction she was going, and she got two grants from us in 1999 and 2000, that helped her work continue on and go the direction that it did. Dr. Neeraj Agarwal: Yeah. And congratulations. Dr. Charles Ryan: Sure. I'll take credit for that one. Dr. Neeraj Agarwal: Being the President and the CEO, you deserve the credit. Dr. Charles Ryan: Sure. That's my job. Dr. Neeraj Agarwal: So, we are coming to the end of the interview, but let me ask you this; the prostate cancer field is so constantly evolving. What is your vision for PCF going forward? Dr. Charles Ryan: Well, my vision for the organization is that we are going to continue on our mission to reduce the death and suffering from prostate cancer. But that's a fairly general statement, and one of the ways you can do that is you can research cancer at a molecular level, and you could try to develop new therapies - we're going to continue to do that. But there's also a real problem, especially, in the United States, and actually globally, with individuals with prostate cancer who are not receiving the cutting-edge care, not receiving the cutting-edge therapy. We have some data that in the United States, maybe upwards of 50% of men with metastatic hormone-sensitive prostate cancer are not getting the therapies that are supported by the latest findings from randomized phase III trials. And this may be for economic reasons, it may be communications or an education deficit with their treating clinicians, and there may be other factors as well. So, as we think about the vision of this, we need to be mindful of that, because if we only focus on studying the cancer molecularly, and we don't address what's happening on the other end, then we're not completing the story, and we're not completing the mission. And so, I've started calling Prostate Cancer Foundation the Global Public Square of Prostate Cancer, because I think of four sides of that square - funding research, as of what we just got done talking about, education and communication, is another one, and we do that in the same way that you are doing this today - through podcasts, and web content, and in-person meetings, as well as applied discovery, which is helping our researchers take their discoveries or their findings out into the clinic. Now, you might think, "Well, that's a small molecule, becoming a company going into a phase I clinical trial." Certainly, that's part of it, but it's also the epidemiologist who is making observations about diet and exercise, who is then empowered to do a clinical trial of exercise and diet intervention. It's also the health services researcher who is able to use their data to go talk to payers or talk to organizations about how care may be delivered differently. So, that's applied discovery. And then finally, supporting the patient is part of what we do. So, we also hold patient webinars every month, we've held patient summits at various points around the country where we bring patients together and talk to them about the latest research or about the factors we've discussed, such as survivorship, or quality of life after treatment, or treatment complications, and things like that. Dr. Neeraj Agarwal: That's wonderful. Thank you so much for sharing your insights. Any final remarks, Dr. Ryan? Dr. Charles Ryan: Dr. Agarwal, thank you so much. It's always a pleasure to speak to another Genitourinary Oncologist, of course, about the field, and the opportunity to talk about the Prostate Cancer Foundation and what we're doing, and the directions we are trying to grow. We've had a great collaboration with ASCO over the years, and I hope that that continues as well. I hope anybody who is interested would come and visit us at: pcf.org, and they can also check us out on: urotoday.com, where we have a lot of content that might be of interest to them. Dr. Neeraj Agarwal: Thank you, Dr. Ryan, for taking the time to be with us on the ASCO Daily News Podcast today. And thank you to our listeners for joining us today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe, wherever you get your podcast. Thank you very much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement. Follow today's Speakers: Dr. Neeraj Agarwal @neerajaimms Dr. Charles Ryan @charlesryanmd Want more related content? Listen to our podcast on therapeutic advances in prostate cancer and other GU cancers.   Advances in Genitourinary Cancers at #ASCO22 Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Neeraj Agarwal:  Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, Gilead Sciences  Research Funding (Inst.): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck , Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas   Dr. Charles Ryan: Honoraria: Janssen Oncology, Bayer Consulting or Advisory Role: Bayer, Dendreon, AAA, Myovant Sciences, Roivant, Clovis Oncology  

Welcome back to our Generation COVID series where we're exploring the impact of the pandemic on pregnant and postpartum parents. In this episode, we're focusing on childbirth and parent mental health. Dr. Amanda Zelechoski interviews Dr. Sharon Dekel and three parents. Together they discuss the pandemic impact on child birthing experiences, the increase in traumatic child births, and the overall mental health challenges new parents have faced in these uncertain times.Additional ResourcesPreeclampsia Foundation7 Symptoms Every Pregnant Woman Should Know (Preeclampsia Foundation)1-833-9-HELP4MOMS – National Maternal Mental Health HotlineLínea Nacional de Asistencia de Salud Mental Materna Para Mamás Primerizas y EmbarazadasFor some women giving birth in the pandemic, the trauma led to personal growth by Juli Fraga (The Washington Post)Meet Our GuestsDr. Sharon Dekel is Assistant Professor of Psychology in the Psychiatry Department at Harvard Medical School and Director of the Postpartum Traumatic Stress Laboratory at Massachusetts General Hospital. She is known internationally for her research on childbirth-related posttraumatic stress. Her work, which has been continually supported by the National Institute of Health (NIH), brings together clinical and developmental psychology, psychophysiology, neuroscience, and machine learning to develop novel screening and interventions for at-risk individuals. Her current project examines the maternal brain and the neural profile that underlies childbirth-related PTSD. She also serves as the principal investigator of the Mothers Wellness study that assesses traumatic childbirth in the outbreak of the COVID-19 pandemic.Dr. Dekel is a two time recipient of the Brain and Behavior Research Foundation's Young Investigator Award; of Harvard's Mind Brain Behavior Awards; and of Mass General's Executive Committee On Research Awards. She was awarded the MGH's Claflin Distinguished Scholar Award for Women in Science and the Postpartum Support International Susan A. Hickman Memorial Research Award for excellence in scientific work on postpartum mental health. Dr. Dekel earned a Ph.D. in Clinical Psychology from Columbia University. She then completed her clinical internship training at Columbia Medical Center and continued to a research postdoctoral fellowship in a lead trauma lab in Israel. Her prior work on the human capacity to thrive in the wake of trauma is considered pioneering in the field. Dr. Dekel also has a private practice in which she treats peripartum individuals.Many thanks to parents Jillian, Stacey, and Dan for sharing their pandemic childbirth and mental health stories in this episode.

Dr Noemi Roy and Dr Roberta Russo present a podcast on the The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper   Dr Roy and Dr Russo discuss the good practice paper in three main parts: 1) Focus on rare anaemias: ( Diamond-Blackfan Anaemia, Congenial dyserythropoietic anaemia (CDA), Sideroblastic anaemia and Red cell membrane/cation leaking and enzyme disorders 2) Next generation sequencing (NGS) 3) How and why we need to interpret genetic variants carefully  The use of next-generation sequencing (NGS) in the diagnosis of rare inherited anaemias is increasingly common, as evidenced by a growing number of publications describing its clinical utility.1-6 Excluding disorders of globin synthesis, rare anaemias include Diamond–Blackfan anaemia (DBA), congenital dyserythropoietic anaemias (CDA), congenital sideroblastic anaemias (CSA) and disorders of red cell membrane and enzymes. Other forms of genetic anaemias can also be considered while establishing NGS panels, in particular genetic syndromes where anaemia comprises one of the constellation of symptoms. Dr Noemi Roy is a Consultant Haematologist at Oxford University Hospitals NSH Foundation Trust and honorary senior clinical lecturer in haematology at the University of Oxford. She is a BSH General Haematology Task Force member and Chair for the Guidelines Executive committee for the European Hematology Association. She is the rare anaemia representative at the National Haemoglobinopathy Panel. Her main interests are haemoglobinopathies and rare inherited anaemias, and in particular the genetic investigation of inherited anaemias, including whole genome sequencing. Dr Roberta Russo is an assistant professor in medical genetics at the University of Naples "Federico II". She has dealt with the study of the genetics of rare disorders, particularly hereditary anaemias, since 2008. Her main interest was the study of Congenital Dyserythropoietic Anaemias (CDAs), mainly CDA type II, genetics and genomics of red cell anaemias and blood cell defects . She contributed first hand to the identification of the causative genes of rare anaemias. Subsequently, she became one of the leading scientists for the genetics and epidemiology of CDAs. Since 2015, she has been dealing with the application of next generation sequencing to the clinical and medical definition of patients affected by this conditions. In 2011, she won the Young Investigator Award by the American Journal of Hematology for her study on the epidemiology of this disorder.

Dr. Mitra Ray is a woman on a mission. She is fiercely committed to being a trusted guide for those who love life, those who want to be healthy and happy, and those who want to live to dance at their grandchildren's wedding. If you are looking for a proven professional who can guide you to better health - with practical and doable solutions that are easy on the wallet in these changing and busy times - then you have come to the right place. With over 30 years of experience, she has helped people achieve remarkable success in feeling better. Dr. Ray received her Bachelor of Science at Cornell University and her PhD from Stanford Medical School. She is the recipient of many NIH grants and the Young Investigator Award from the Federation of American Societies in Experimental Biology. Her research has been published in such prestigious journals as Science, Proceedings of the National Academy of Sciences and the Journal of Cell Biology. Audiences in 4 continents have enjoyed her award-winning books, audios and lectures on nutrition, stress reduction, brain function and longevity. She is the CEO and CoFounder of rREST Inc, an emotional wellness startup company committed to bringing a disruptive technology in neuroemotional psychology to millions and help them reprogram childhood stress patterns. rREST has received a Google Social Impact Grant to help bring awareness of this technology to the public.

In this episode, I am joined by 2 women who have been in my world and my life for quite a long time, and who have so much knowledge and wisdom to share – Nicole Scott & Dr. Mitra Ray. Nicole Scott is a Holistic Nutritionist, Pro Aging Advocate, Author, International Wellness speaker, Global Network Marketing Professional and mom of 2 teenage girls. Dr. Mitra Ray, with over 30 years of experience, has helped people achieve remarkable success in looking and feeling better. Dr. Ray received her Bachelors of Science at Cornell University and her PhD from Stanford Medical School. Today we chat about all things micronutrition and how to create opportunity and abundance in your life. Are you ready for this eye-opening conversation?   Connect with us - Thank you for joining us today. If you could do me the honor of hitting the subscribe button, leaving a review, sharing this podcast with a friend, or tagging me on social media when you visit The Simplicity Sessions Community on Facebook or @jennpike on Instagram, I would be forever grateful. Connect with our Guests - Nicole Scott Nicole Scott is a Holistic Nutritionist, Pro Ageing Advocate, Author, International Wellness speaker, Global Network Marketing Professional and mom of 2 teenage girls. Website: nicolescott.ca Grab the Gray Hair Transition Guide: https://aw1a22c4.aweb.page/p/e9acb6ea-6e16-499e-893e-c08fcd597f30 Instagram: @gorgeousgreymovement @designasweetlife   Dr. Mitra Ray With over 30 years of experience, she has helped people achieve remarkable success in looking and feeling better. Dr. Ray received her Bachelors of Science at Cornell University and her PhD from Stanford Medical School. She is the recipient of many NIH grants and the Young Investigator Award from the Federation of American Societies in Experimental Biology. Her research has been published in such prestigious journals as Science, Proceedings of the National Academy of Sciences and the Journal of Cell Biology. Audiences in 4 continents have enjoyed her award winning books, audios and lectures on health, beauty, brain function and longevity. Her mission and commitment is to educate and inspire people about how plant-based, whole foods create simple, sustainable beauty, mental clarity and vitality. Website: drmitraray.com Instagram: @drmitraray Learn more about the products and supports I recommend from some of our amazing partners - Eaton Hemp is my favourite CBD and hemp company. They are a hundred percent organic, they're unfiltered, and they are third-party tested. To experience Eaton Hemp, use the discount code JENNPIKE20 at eatonhemp.com/jennpike to save 20% off your order. St Francis Herb Farm education includes webinars, blogs and articles on important topics including the plant medicines that they create to promote women's health by targeting digestion, allergies, immune support, heart health, brain health, and sleep. I use and recommend their products and you can use the code JENNPIKE15 at checkout to save 15% off your order. GoodJuju makes all-natural, plastic-free home & body products that are good for you and good for the planet. Use JENNPIKE10 for 10% off your order. Skin Essence is Canadian-founded, organic, non-GMO, and does not test on animals; this company is one that we love and have around the house. You can even talk to the company to get advice on which products may be right to try first. Save 15% off your first order with the code JENNPIKE15 and use code JENNPIKE10 to save 10% off every order after that.

Discussion of a new, early phase clinical trial for patients with metastatic osteosarcoma targeting the DNA damage repair pathway. Dr. Vishu Avutu attained his M.D. from the University of Texas Southwestern Medical School and began his research endeavors with the Pediatric Oncology Education Program at St. Jude Children's Research Hospital; finding a passion for working with adolescents and young adults, Vishu matched to the internal medicine-pediatric residency at Harvard's Brigham and Women's/Boston Children's Hospitals. In addition to serving as Chief Resident, Vishu helped develop and launch the Center for Adolescent and Young Adult Oncology at the Dana Farber Cancer Institute. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center. He is a co-founder of MSK's Adolescent and Young Adult Oncology Program, where his work has garnered MSK's Patient and Family Centered Care Grant Initiative and the Young Investigator Award from the American Society of Clinical Oncology. He is an assistant attending in the Departments of Medicine and Pediatrics and cares for AYAs with sarcomas.

Today on Breast Cancer Conversations I'm joined by Dr. Bardia, a Board Certified Medical Oncologist interested in developing successful, targeted and personalized therapies to improve the outcomes of patients and families affected by breast cancer. Dr. Bardia is involved in clinical development of tumor genotyping, as well as circulating tumor cells to facilitate accurate diagnosis, therapy selection, and real time monitoring of breast cancer. Dr. Bardia is the primary investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer, and is the recipient of the Young Investigator Award from ASCO Conquer Cancer Foundation. I am also joined by two other amazing women, Janice Cowden and Keegan Hitchcock, both living with metastatic TNBC. Janice was diagnosed with stage four metastatic triple negative breast cancer in 2016. With a 20 plus year background in nursing, science, research and studying disease, it is no surprise that Janice became a Patient Advocate. Her advocacy work has included working with organizations like METAvivor, Living Beyond Breast Cancer, ABCD after breast cancer diagnosis, among others. I am also so excited because I am joined by Keegan Hitchcock. Keegan is 41 years old, born and raised in Florida, where she had a professional career as a face and body painter for over 20 years. Her interests include reading and consuming lots of podcasts, including anything from spooky stories and humor, to the lesser known history, critical thinking and science. She loves watching and discussing nerdy TV shows and movies with friends, roller-skating, and spoiling her two cats. She now lives in Maryland near family where she continues to work at a national health food store doing price integrity. Her original diagnosis was in May of 2019 with stage three triple negative invasive ductal carcinoma.  As of April 2021, she has been re-diagnosed with a recurrence stage four metastatic triple negative breast cancer.Welcome to the conversation.

Dr. Paul A. Offit, MD, (https://www.paul-offit.com/) is an internationally recognized expert in the fields of virology and immunology, Co-Inventor of a landmark vaccine for the prevention of Rotavirus gastroenteritis, and holds multiple titles including - Director of the Vaccine Education Center at Children's Hospital Of Philadelphia (CHOP), Maurice R. Hilleman Chair of Vaccinology and Professor of Pediatrics, Perelmann School of Medicine, University of Pennsylvania, and Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology. Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines. Dr. Offit is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of a landmark rotavirus vaccine recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In addition, he has received numerous other awards and honors for his groundbreaking work. Dr. Offit is also an author of many books including, but not limited to: Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases, Overkill: When Modern Medicine Goes Too Far, The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis, Breaking the Antibiotic Habit, Do You Believe in Magic, and his most recent, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation.

There's no better way to kick off September as the Pain Awareness Month than bringing you a conversation with Dr. Kanwaljeet S. Anand, whose research took the medical world by storm, even risking his license, as he sought out to answer the question of; what if we give children anesthesia and analgesia?  I truly believe that he is the reason why my career as a pediatric pain and palliative care physician exists today and serves as an available path for many healthcare professionals. In this episode,  Dr.  Anand, a professor of Pediatrics, Anesthesiology, Perioperative, and Pain Medicine at Stanford University School of Medicine, describes his groundbreaking research back in the 80s, when a popular held belief was that babies don't feel pain!  With the findings  and intervention offered in his RCT, they were able to cut down the infant mortality rates by half.  It is the work of doctors like him that paved the path for someone like me to practice pediatric pain management as a specialty-- hoping to save and improve the lives of many more children by debunking the fallacies that still surround children's pain and its management.   Takeaways In This Episode   What fueled Dr. Anand's desire to research perioperative care for infants His hypothesis around morbidity and mortality of neonates and infants undergoing surgeries, relationship to anesthetic management  Conducting the randomized controlled trial study and its results that changed the history and trajectory of childrens pain and perioperative management Sometimes it's worth picking the fights How his study gained momentum and changed how the healthcare world approaches pain management for children and infants When and how infants develop the ability to feel pain The long-term consequences of poorly or inadequately  managing children's pain Changing the minds of colleagues who perpetuate the belief that children are “hardy” and will “get over it” Dr. Anand's message to the audience   Links Connect with Dr. Kanwaljeet S. Anand: Stanford Profile LinkedIn Love, Pain, and Intensive Care. K.J.S. Anand, Richard W. Hall Clinicians' Pain Evaluation Toolkit Proactive Pain Solutions   About the Guest    Kanwaljeet S. Anand, MBBS, MD, D Phil, FRCCM   He is currently the professor of Pediatrics, Anesthesiology, Perioperative, and Pain Medicine at Stanford University School of Medicine. He directs the pain and stress neurobiology lab, the Jackson Vaughan Critical Care Research Fund, and he serves as the Editor of the journal Pediatric Research and is the Division Chief for Pediatric Critical Care at the Department of Pediatrics at Standford School of Medicine. He graduated from M.G.M. Medical College, Indore (India). He received the D.Phil. degree as a Rhodes Scholar at the University of Oxford, followed by a post-doctoral fellowship at Harvard Medical School, a categorical Pediatrics residency training at Boston Children's Hospital, and a Critical Care Medicine fellowship at Massachusetts General Hospital in Boston. He is the recipient of innumerable awards, including the Dr. Michael Blacow Award from the British Pediatric Association in 1986, the Pediatric Resident Research Award from the American Academy of Pediatrics, the inaugural Young Investigator Award in Pediatric Pain from the International Association for Study of Pain in 1994, the Jeffrey Lawson Award for advocacy of children's pain relief, the highest recognition in pediatric pain medicine in the United States. He's also been awarded many awards across Europe in many countries such as the Nils Rosén von Rosenstein Award from the Swedish Academy of Medicine and the 2015 Journées Nationales de Néonatologie Address at The Pasteur Institute to name a few. For his dedication and work in the field of pediatric pain management, he is considered a world authority on pain and stress in newborns and pain management in infants. 

In Episode 12 of Bladder Cancer Matters, Rick Bangs's special guest is Samuel L. Washington III, MD, MAS, of the University of California San Francisco Department of Urology. Dr. Washington is Assistant Professor of Urology, Goldberg-Benioff Endowed Professorship in Cancer Biology, and a recipient of BCAN's Young Investigator Award. Rick and Dr. Washington discuss: Why should patients get a second opinion? Are there ever good reasons to NOT get a second opinion? Will my doctor support me getting a second opinion? What do you/should you tell the patient as a clinician when you hear them say they want to do this? What if the first and second opinions disagree?  

In this episode, I talk with Professors Kristen Bottema-Beutel and Micheal Sandbank, who have done a systematic review and meta-analysis of 151 group design studies of interventions for young autistic children. For this work, Dr. Sandbank was awarded the Young Investigator Award in 2021 from the International Society of Autism Research. Drs Bottema-Beutel and Sandbank … Continue reading On conflicts of interest in autism research: Interview with Kristen Bottema-Beutel and Micheal Sandbank

Centosessantasettesima puntata della trasmissione "Generazione Mobile" di Radio 24, il primo "passaporto radiofonico valido per l'espatrio". In questa puntata: - Francesca Barbieri, giornalista de "Il Sole 24 Ore", torna a segnalarci le più recenti opportunità di formazione e lavoro all'estero, all'interno della rubrica Toolbox; - Patrizia Mondello, ricercatrice 35enne nel settore oncologico negli Stati Uniti, fresca vincitrice dello "2020 Young Investigator Award" dell'ISSNAF, ci spiega come avviare una carriera di successo nella ricerca medica Oltreoceano; - Eures Italia ci aggiorna sulle prossime opportunità e selezioni per lavorare in Europa; - in Internet Point vi parliamo di un progetto, che mira a portare la cultura italiana nelle case dei connazionali all'estero, attraverso i libri. O meglio, i libri per bambini. Il suo nome è "Sgrunf - Kids Box": con noi la co-founder Anna Sommavilla. CONNETTITI CON "GENERAZIONE MOBILE" Studiate/lavorate/siete imprenditori all'estero? E siete "under 40"? Avete una storia da raccontare e consigli preziosi da dare per cogliere opportunità oltreconfine, sfruttando le occasioni di mobilità internazionale?Scrivete a: generazionemobile@radio24.it Oppure, avete domande da porre su come studiare/fare stage/lavorare/avviare start-up all'estero?Inviatele a: generazionemobile@radio24.it Infine, avete un sito/blog all'estero, nel quale fornite consigli pratici su come trasferirsi nel vostro attuale Paese di residenza? O avete scritto un libro su questo tema?Segnalateci tutto, sempre a: generazionemobile@radio24.it

Centosessantasettesima puntata della trasmissione "Generazione Mobile" di Radio 24, il primo "passaporto radiofonico valido per l'espatrio". In questa puntata: - Francesca Barbieri, giornalista de "Il Sole 24 Ore", torna a segnalarci le più recenti opportunità di formazione e lavoro all'estero, all'interno della rubrica Toolbox; - Patrizia Mondello, ricercatrice 35enne nel settore oncologico negli Stati Uniti, fresca vincitrice dello "2020 Young Investigator Award" dell'ISSNAF, ci spiega come avviare una carriera di successo nella ricerca medica Oltreoceano; - Eures Italia ci aggiorna sulle prossime opportunità e selezioni per lavorare in Europa; - in Internet Point vi parliamo di un progetto, che mira a portare la cultura italiana nelle case dei connazionali all'estero, attraverso i libri. O meglio, i libri per bambini. Il suo nome è "Sgrunf - Kids Box": con noi la co-founder Anna Sommavilla. CONNETTITI CON "GENERAZIONE MOBILE" Studiate/lavorate/siete imprenditori all'estero? E siete "under 40"? Avete una storia da raccontare e consigli preziosi da dare per cogliere opportunità oltreconfine, sfruttando le occasioni di mobilità internazionale?Scrivete a: generazionemobile@radio24.it Oppure, avete domande da porre su come studiare/fare stage/lavorare/avviare start-up all'estero?Inviatele a: generazionemobile@radio24.it Infine, avete un sito/blog all'estero, nel quale fornite consigli pratici su come trasferirsi nel vostro attuale Paese di residenza? O avete scritto un libro su questo tema?Segnalateci tutto, sempre a: generazionemobile@radio24.it

Dr. Kleiner is the owner of High Performance Nutrition®, LLC, a consulting firm in Mercer Island, Washington. She is the Director of Science & Communication for Vitargo, Inc., and the High Performance Nutritionist for Seattle Storm. Dr. Kleiner is the author of eight books, including THE NEW POWER EATING®, The Good Mood Diet®, and POWERFOOD Nutrition.   She has a PhD in Nutrition and Human Performance and is a registered dietician, certified nutrition specialist, Co-Founder and Fellow of the International Society of Sports Nutrition, and a Fellow at the American College of Nutrition, where she received a Young Investigator Award for her research. She has been a member of the National Strength and Conditioning Association and the American College of Sports Medicine for decades.   “What I do is help people achieve peak performance from the locker room to the boardroom to the bedroom.” Dr. Kleiner’s world is nutrition and human performance and believes that appearance or body composition should be an athlete’s secondary priority. In fact, she focuses on body composition insofar as it contributes to performance.   “Translating the science of nutrition into food is the particular skill of a good dietician,” says Dr. Kleiner. To this end, she has always taught her clients about food from the get-go so that they think about their daily food intake in terms of the food itself rather than simply counting macros and calories. She is an advocate of what she calls “power eating”, or eating more instead of restricting yourself in order to gain greater energy, train harder, and, if part of your goal, lose fat.   Whether you are an elite athlete or someone who just wants to increase performance in mind and body, listen in as Dr. Kleiner shares her philosophies and ideas around nutrition that can help you reach your fitness goals without having to worry about your diet.   Key Highlights What is performance training and nutrition for performance training? What are some of the biggest mistakes athletes make when training for performance that they are making in their nutrition? When it comes to training for performance, should the focus be on maximizing carbohydrate intake or caloric intake? And how does nutrient timing factor into nutrition for performance training? How do you go through a cut or weight/fat loss regime while maintaining your mood? How can we navigate a world obsessed with body image and generally misinformed when it comes to healthy eating?   Episode resources: Get your free LMNT Recharge sample pack at https://www.drinklmnt.com/everforward  Get The New Power Eating book Learn more about Dr. Susan Kleiner

We just spent some time talking about triggers and how we need to find the root of the problem to solve it. To take it a step further, I’ve invited Dr. Mitra Ray to chat with me about rRest therapy. Like she says in today’s episode, you have to yank the original source of the trigger out by its roots or it will just keep popping up.   With over 30 years of experience, Dr. Mitra Ray has helped people achieve remarkable success in looking and feeling better. She received her Bachelors of Science at Cornell University and her PhD from Stanford Medical School. She is the recipient of many NIH grants and the Young Investigator Award from the Federation of American Societies in Experimental Biology. Her research has been published in such prestigious journals as Science, Proceedings of the National Academy of Sciences and the Journal of Cell Biology. Audiences in 4 continents have enjoyed her award winning books, audios and lectures on health, beauty, brain function and longevity. Her mission and commitment is to educate and inspire people about how plant-based, whole foods create simple, sustainable beauty, mental clarity and vitality. Her latest book, Do You Have the Guts to Be Beautiful was featured in Women’s Health magazine going out to millions of readers and is available on Amazon. Show Notes: [2:57] - Welcome to the show, Dr. Ray! Mitra loves to talk about rest and she shares her background regarding her neuroscience work regarding the study of rest. [4:18] - Dr. Ray shares the experience of Dr. Cindy Sholes that sparked the curiosity regarding rest and the brain’s reactions to stimuli. [5:35] - Mitra was a guinea pig for various studies on rRest and the technology used saved her from quitting herself. [7:41] - There are so many things that rRest helps with - physical pain, emotional stress, trauma, and more. [8:38] - Something that Mitra has discovered through her work with rRest is that we do not respect the fact that children have complex emotions. [9:47] - Growth doesn’t just belong to those who had a rough childhood. Jill and Mitra discuss the fact that rRest isn’t just for childhood trauma. You had a childhood, period, and everyone has work to do. [10:08] - Jill shares her experience with talk therapy but admits that she still did not get the results she needed until she and her son started rRest therapy. [11:53] - Most of the time, people don’t truly understand why they feel the way they do. [12:34] - During a rRest session, you do not relive any childhood trauma. Dr. Ray describes how the technology works and compares it to a lie detector test. [14:16] - Dr. Ray describes muscle testing and looks at the emotions associated with statements they go through. The statements are like a gateway to the subconscious mind to help find triggers. [15:11] - rRest sessions can even bring emotions back as far as being in utero. [16:08] - Dr. Ray can clear an emotional memory and all negativity surrounding the statements they go through in a session. Using the same example, Dr. Ray describes what happens after this occurs.  [16:58] - If a scan is done before and after a rRest session, it is clear that emotions are firing differently. [18:14] - There’s no work involved in this. Through a session, an emotion is found without reliving the memory and the brain brings it to the front of the brain to process. [19:22] - The exact memory and all the details doesn’t matter to rRest therapy. Mitra explains that all that’s necessary is a “black and white sketch” of the problem. [20:55] - The past lives in your mind. If your mind is being rewired, you are literally becoming a different person. [21:19] - If you didn’t have all this emotional clutter, you would be amazed at how brilliant and beautiful and amazing you are. That’s the real you. [22:17] - Jill shared her experience with a rRest therapy session. [23:44] - Seemingly insignificant memories do impact our emotions as an adult.  [24:46] - Jill describes her fear of abandonment and how her memories became triggers for panic as an adult. [26:03] - You are never really mad about something that is happening now. You are triggered by something happening now and taken back to an emotion you’ve felt in the past. Talk therapy only brings you back to a single memory and probably not the memory that is being triggered. [27:29] - Dr. Ray describes the neuroscience process of rRest therapy and how “yanking” the first time experiencing the emotion out solves the problem almost immediately. [30:04] - We figure out how to survive by being tough and compartmentalizing, but Dr. Ray explains that it doesn’t have to be that way. [31:20] - Using a soldier experiencing PTSD to relive events over and over again is not useful or healthy. The therapy is to find the original event that created a PTSD response to events as an adult. [34:04] - Mitra and Jill discuss the physical health side effects that happen when we don’t process emotions, stress, and triggers. [35:53] - Dr. Ray explains how rRest therapy actually caused her to stop drinking before she even knew she needed or wanted to. [37:13] - Imagine if everyone can be joyful and free.  I know there was something in this episode that you were meant to hear. Let me know what that is. Thank you for being here today with me on our healing journeys. Links and Resources: Be You Home Page Jill Herman on Instagram Be You Collective on Facebook My Best Year Ever Workshop Recording   Don’t forget to download your free ebook to help you discover how to live a life of POWER, FREEDOM, and JOY! Be You and Break Free From the Opinions of Others by Jill Herman   rRest Technique Home Page Dr. Mitra Ray Home Page Dr. Mitra Ray on Facebook Dr. Mitra Ray on Twitter

Dr. Audrey Dussutour is a National Center for Scientific Research (CNRS) Scientist at Paul Sabatier University in Toulouse, France. Audrey studies animal behavior and collective intelligence in ant colonies and slime molds. In ant colonies, she examines how the ants regulate traffic to avoid traffic jams, and she creates algorithms that may help alleviate our own traffic jams. In slime molds, Audrey investigates the different cognitive abilities they are able to display even though they don’t have brains. Outside work, Audrey loves going out to the movies and watching DVDs. Some of her favorite directors are John Cassavetes and David Lynch, and she gets into sci-fi films as well. Audrey received a Masters Degrees in Ecology from Paul Sabatier University, a Masters Degree in Neurosciences and Ethology from the Free University of Brussels in Belgium, and a PhD in Animal Behavior working in laboratories from both of these universities. She next conducted postdoctoral research at Concordia University in Canada and at the University of Sydney in Australia. Audrey has received numerous awards and honors for her exceptional work, including the Adolphe Wetrems Award of the Belgian Royal Academy, the Young Investigator Award of the French Society for the Study of Animal Behavior, the Outstanding Paper Prize from the Journal of Experimental Biology, Lauréate du Prix Le Monde de la Recherche, and the Young Researcher Prize from the French Society for the Study of Animal Behavior. Audrey joined us for an interview to talk about her experiences in life and science.

This month on Episode 19 of the Discover CircRes podcast, host Cindy St. Hilaire highlights three featured articles from the December 4 issue of Circulation Research. This episode features an in-depth conversation with Drs Mete Civelek and Redouane Aherrahrou, from the University of Virginia regarding their study titled Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells.   Article highlights:   Zahreddine, et al. Tamoxifen and E2 Effects On Reendothelialization   Zheng, et al. Arterial Stiffness Preceding Diabetes   Galang, et al. ATAC-seq Identifies Novel Isl1 SAN Enhancer   Cindy St. Hilaire:              Hi, welcome to Discover CircRes, the podcast to The American Heart Association’s journal, Circulation Research. I'm your host, Dr Cindy St. Hilaire from The Vascular Medicine Institute at the University of Pittsburgh, and today I will be highlighting three articles selected from the December 4’th issue of Circ Res. Drs Mete Civelek and Redouane Aherrahrou, from the University of Virginia, are here to discuss their study, Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells. Cindy St. Hilaire:              The first article I want to share is titled, Tamoxifen Accelerates Endothelial Healing by Targeting Estrogen Receptor-alpha in Smooth Muscle Cells. The first author is Rana Zahreddine, and the corresponding author is John Francois Arnal and they're from INSERM and the University of Toulouse, France. For breast cancers that contain high levels of estrogen receptor, a standard treatment is to give drugs that block either estrogen production or the receptor itself, such as tamoxifen. However, estrogen can elicit beneficial vascular protective effects, so treatment with tamoxifen might increase the risk of cardiovascular disease. Depending on the tissue, tamoxifen can both antagonize or activate estrogen receptor, so it's role in cardiovascular disease is unclear. Cindy St. Hilaire:              Some evidence even suggest tamoxifen might have protective effects, such as promoting vascular endothelial healing. Zahreddine and colleagues now show that while might suffering damage to the endothelial lining of a blood vessel have improved healing when treated with tamoxifen, or with estrogen, those suffering perivascular injury, that is to say, the injury that affects both the endothelial layer as well as the surrounding smooth muscle cell layer, heal only in response to estrogen. This suggests tamoxifen's healing effects might require smooth muscle cells. In mice, lacking the estrogen receptor and smooth muscle cells, they found estrogen, but not tamoxifen, healed endovascular injuries. While in mice lacking estrogen receptor and endothelial cells alone, they found the opposite. This work reveals nuances in the molecular actions of tamoxifen that should inform further assessment of its risk and benefits for use in patients. Cindy St. Hilaire:              The second article I want to share is titled, Arterial Stiffness Proceeding Diabetes, A Longitudinal Study. The first authors are Mengyi Zheng and Xinyuan Zhang and the corresponding authors are Xiang Gao and Shouling Wu, from Pennsylvania State University and North China University of Science and Technology. As a person ages, their risk of developing diabetes and cardiovascular disease increases. Aging is also linked to increase in arterial stiffness and high blood pressure, but how all these individual conditions affect and influence each other is not entirely clear. For example, while arterial stiffness and diabetes tend to correlate, whether one increases the risk, or the other, or the risk relationship or whether the risk relationship is bi-directional, is unknown. Cindy St. Hilaire:              To assess the interplay between these disease states, Zheng and colleagues studied diabetes and arterial stiffness in a cohort of 8,956 Chinese people between 2010 and 2015, none of whom had had diabetes or cardiovascular disease at the outset of the study. With repeated measures of fasting glucose levels, which is an indicator of diabetes, and pulse wave velocity, which is a measure of arterial stiffness, the team found that participants with a higher baseline arterial stiffness were more likely to develop diabetes during the five-year period than those with lower stiffness levels. Out of the original cohort of just over 8,900 individuals, a total of 979 individuals developed diabetes during the study. Higher baseline glucose levels did not predict future arterial stiffness; this suggests a risk relationship that is a one-way street. While the results require confirmation in additional cohorts, this finding is the first to identify the pathological mechanisms linking arterial stiffness to diabetes.  Cindy St. Hilaire:             The third article I want to share is titled, ATAC-Seq Reveals an ISL1 Enhancer That Regulates Sinoatrial Node Development and Function. The first author is Giselle Galang, Ravi Mandla, and Hongmei Ruan. And the corresponding author is Vasanth Vedantham, from the University of California, San Francisco. Pacemaker cells, of the sinoatrial node, establish and control the rhythmic contractions of the heart. These cells differ from regular cardiomyocytes in their transcription profiles, but how this transcriptional profile is established and maintained is not fully understood. To investigate the epigenetic landscape defining pacemaker cell fate, Galang and colleagues have employed a technique called ATAC-Seq, which identifies areas of the genome with accessible open chromatin structures, which is an indication of transcriptional activity. The team compared the genomes of pacemaker cells with atrial cardiomyocytes, and found a number of pacemaker cell-specific accessible loci that had both large numbers of transcription factor binding sequences and enhancer activity, when assayed in mice. Cindy St. Hilaire:              The team went on to specifically characterize one novel enhancer upstream of the gene, encoding ISL1, which is a key transcription factor for pacemaker cell identity. They showed that deleting the enhancer caused under development of the Sinoatrial node and arrhythmias in mice. They also noted that single cell nucleotide polymorphisms at the equivalent loci in humans, have been linked to variations in resting heart rate. The report verifies ATAC-Seq as an effective tool for identifying pacemaker enhancers and will launch future studies into how such enhancers function in heart development and disease. Cindy St. Hilaire:              Okay, so today with me is Dr Mete Civelek and Dr Redouane Aherrahrou, from the University of Virginia, and they're here to discuss their paper titled, Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells. And this article is featured in our December 4th issue. So thank you both so much for being here with me today. Mete Civelek:                   Great to talk to you Cindy. Thank you for choosing our paper. Cindy St. Hilaire:              Yeah, and seeing you over Zoom, I wish these were in person, but... Redouane Aherrahrou:  Thank you for having us. Cindy St. Hilaire:              Yeah. Great. So, before we dig into the details of this paper, which I think is a really nice paper, one of the things I like about it is that it couples GWAS with some functional things, which is obviously super important for figuring out what is important in that GWAS data. So, before we dig into the nitty-gritty of the paper, could you maybe explain what a GWAS study is, and what the strengths and weaknesses are, in terms of using that as an approach to figure out disease related pathophysiology? Mete Civelek:                   So, we know that coronary artery disease, or these cardio-metabolic diseases, have a genetic component, and in the past we used to do linkage studies, studying families, but in the last 15 years or so, because of the developments in technology, we can do these genome-wide association studies. And essentially what they do is they look at a population and some of the people in the population will have coronary artery disease and some people will not have coronary artery disease, will be otherwise healthy. And then you study the genetic variance across the entire genome and look for frequency differences in the people with the healthy phenotype and people who have the disease. And of course you do some statistical tests to find if this frequency differences is indeed statistic, the different between these two groups and you identify essentially loci that are associated with the disease. Mete Civelek:                   But I see GWAS as almost a detective work, you say something like, okay, let's say there was a murder in the United States, and then now you do GWAS of course to find the murder, right? But what that tells you is, okay, the murder occurred in, let's say Pittsburgh or Charlottesville or Washington DC, sure, it narrows down the scope of where you're going to look at, but it doesn't tell you exactly what happened and where it happened and things like that. And so after GWAS there many more questions to answer looking at the molecular mechanism of the locus, the tissue or cell type of action, the gene, which is being affected by the locus to affect the phenotype. So, it's very good at narrowing down possibilities and coming up with hypotheses, but then the real work begins. Cindy St. Hilaire:              I was wondering actually, as you were saying that, have there ever been... I guess like false discoveries, where people have really focused in, on a loci, because it came up maybe in one or multiple studies, but then maybe it didn't prove to be causative or they still can't figure it out. Are there examples of that? Mete Civelek:                   The most obvious example is actually the 9p21 locus. Cindy St. Hilaire:              Interesting. That's the one I was thinking of actually. Mete Civelek:                   Which has been associated with coronary artery disease susceptibility in all kinds of studies and in kinds of populations, this signal itself is real, what it's doing is been a lot of debate. Some people think that it's affecting the CDKN2A and 2B genes nearby. Cindy St. Hilaire:              Is that p21 or p16? Mete Civelek:                   One is p21 and one is p16, but I can't remember which one. Cindy St. Hilaire:              Yeah, I can't either. Mete Civelek:                   Right. And then there's a non-coding RNA in that region called lnRNA. Some people think it's affecting and lncRNA expression. Some people think it's affecting isoform abundance, so that's just probably the most famous locus in our field, in terms of figuring out what it's doing. Yeah. Cindy St. Hilaire:              Well, at least it's probably causing a lot of people to think of a lot of good questions to ask, so that's exciting. In your study, you state that you want to focus on the impact of coronary artery disease associated variants in atherosclerosis-relevant smooth muscle cell phenotypes, and the phenotypes you wanted to focus on were calcification, which is my personal favorite. So calcification, proliferation, and migration. So I was wondering why you wanted to focus on these phenotypes and then what kind of functional assays did you do? Redouane Aherrahrou:  So, the reason we choose those phenotypes because they are playing important role in the disease. So, for example, during the advanced stage of the disease, smooth muscles cells, they proliferate and migrate to make the fibrous cap. So the fibrous cap is actually stabilize the plaque against the rupture, and also during the advanced stage of the disease, the calcification also happening, a lot of people believe that the calcification also contribute to instability of the fibrous cap. So that's why we focus on those three phenotype, migration, proliferation, and calcification. Cindy St. Hilaire:              Interesting, and so I think you'd said you had about 150 patients in your study. Does that mean you did these functional assays in 150 different cell lines? Or how did you do that? Redouane Aherrahrou:  That's a good question. So we conducted actually, our assays from 150 healthy and multi-ethnic donors, so those people actually did die from motorcycle and car accidents, and the doctors actually use the chunk of the aorta where we'll actually isolate these cells from, and then they are actually healthy enough to use for the heart transplantation. Cindy St. Hilaire:              Wow. And so were you introducing known SNPs or SNPs that are pulled out of GWAS into the cells, or did the cells already have the SNPs available? How was the correlation done between functionality and SNPs? Redouane Aherrahrou:  That's a great question. So we actually use the natural SNPs that already exist in those donors. And we ask the question how the genetic variants of those donor affects migration, proliferation, and calcification phenotypes. Mete Civelek:                   So we essentially perform a GWAS in a dish- Cindy St. Hilaire:              Yeah, that's kind of what I was thinking- Mete Civelek:                   That's the bottom line, you just culture these cells and do these phenotypic characterizations, which you cannot do in healthy living human beings of course, and then just the naturally occurring genetic variation in these individuals, in these donors, to essentially calculate the association between the genetic variants and then these phenotypes. Cindy St. Hilaire:              And you were using aortic smooth muscle cells, right? Mete Civelek:                   Yes. Cindy St. Hilaire:              Do you think... this is one thing I always think about, especially because kind of harping back to Mark Majesky's early work with the chick embryo and developmental origins. Do you think if you had coronary arteries from the same individuals that the smooth muscle cells would respond similarly? Mete Civelek:                   This is a really good question, partially, yes and partially, no. I'll give you one specific example, for example, one of the loci that is associated with coronary artery disease is over a transcription factor called TCF21. And TCF21 is actually playing an important role in smooth muscle cell phenotypes, and that transcription factor is expressed only in coronary artery smooth muscle cells, but not in aortic smooth muscle cells. Cindy St. Hilaire:              Interesting. Mete Civelek:                   This was something that Dr Tom Quertermous from Stanford showed. So presumably we are capturing some of the genetic variation that's important in coronary artery disease as some of it was probably missing because we're using aortic smooth muscle cells. Cindy St. Hilaire:              Yeah. That is so neat. I really like that heat map you had, I think it was figure 4 because you really lined up along the SNPs that were identified in these patients you looked at the effect of that SNPs on a specific function test, you did, and you did, was it 11 functional tests? Mete Civelek:                   12 different functional tests. Cindy St. Hilaire:              12? Mete Civelek:                   Yes. Cindy St. Hilaire:              It's an amazing amount of work really. Well, how long have you been working on this project? Mete Civelek:                   Redouane, why don't you answer this question? Cindy St. Hilaire:              Or do you not want to talk about that? Redouane Aherrahrou:  Of course, it's not easy actually to culture and characterize 151 smooth muscle because you expect sometimes, you capture them, some of them, they will not grow, some of them they get contaminated, and you have to perform it again. And also, you cannot do the same experiment for all of them at the same time. So what we did actually, before we started the experiments, we decided to take a smooth muscle cell from one donor, and expanded many times and then we use the same donor to run each time for all the experiments, just to count for the batch and environment effects. Cindy St. Hilaire:              Yep. Redouane Aherrahrou:  So it took me actually almost one and a half year, to finish the characterization for all 151 smooth muscle cell. At that time I was also using also two incubators and then you can imagine, when you put the incubator- Cindy St. Hilaire:              It's full. Redouane Aherrahrou:  ...and I try to finish that, and then I again, start the experiment again to finish the other batch. Cindy St. Hilaire:              Oh God. Yeah, my lab also... we work only in primary human tissues from vessels, but also from valves. So my staff will certainly appreciate all your efforts for this paper. Mete Civelek:                   And you can also imagine there was this group of undergraduates, trailing- Cindy St. Hilaire:              An army yeah. Mete Civelek:                   Redouane wherever he goes….they were helping him out with many aspects. Cindy St. Hilaire:              Oh, sure that's amazing- Mete Civelek:                   He mentored, I think maybe five, six different undergraduate students throughout this project and they're all part of the paper. Yeah. Cindy St. Hilaire:              That's excellent. So towards the end of the study, you guys really focused on a gene, MIA3. So can we talk a little bit about that? What is this gene? What its normal function? Is it known? And then what did you find out in relation to smooth muscle cells? Mete Civelek:                   Well, I'll start and Redouane you can continue. So let me just walk back just a little bit to tell you how we kind of decided to focus on that. So we identified the 79 loci that are associated with smooth muscle cell phenotypes and coronary artery disease. So we wanted to show at least some kind of a validation and so we looked for loci that are not associated with lipids because we thought they will maybe not be important in smooth muscle cells. And then we then looked for loci out of those, who affect a nearby gene expression in aorta, in smooth muscle cells, but not in endothelial cells and in monocyte so we thought that will give us confidence- Cindy St. Hilaire:              So kind of enriching for this smooth muscle cell? Mete Civelek:                   And this MIA3 popped up and there was only one study actually that showed that, in codes for protein that localizes to the ER exit site and affects these COPII carriers, which secrete collagen into extracellular matrix. Well, collagen as you know, is important in cell stability and what smooth cell muscle cells produced. So, that's how we decided to focus on that gene. And I will let Redouane describe I guess, what we did with that gene. Redouane Aherrahrou:  Yeah. So after the function and mutation, we come up with this gene. So the first thing we did, because we found that the genetic variety in this locus affects actually proliferation in smooth muscle cell. So to what it did at least, this is actually SNP that's affecting the proliferation of smooth muscle cell by this gene, we down-regulate this gene actually in smooth muscle cell using two different shRNA, and we found actually the downregulation of this gene lead to affect the proliferation in sense that dominant regulation of this gene will affect the proliferation. Redouane Aherrahrou:  And also we found that the same genetic variance also in this gene lead to lower periphery, migration, sorry, the expression of this gene in small as I said, and then also in the aortic tissue. And interestingly, we did not see in the monocytes macrophages or other cell type, actually in the aortic tissue suggesting that this genetic variance affecting the coronary artery disease via smooth muscle cell. Mete Civelek:                   And we also collaborated with Renu Virmani's group at CVPath Institute, stained lesions, coronary artery lesions, which have these thick caps and thin caps as you very well know that is really relevant to plaque stability, and show that the thin caps have fewer smooth muscle cells which were positive for this protein MIA3, which was all in line with our genetic findings, because our genetic findings basically show that lower expression of this gene was associated with increased susceptibility to coronary artery disease. Cindy St. Hilaire:              Interesting. I wonder if it could be correlated with plaque rupture, right. If there's less smooth muscle cell, obviously, then a thin fibrous cap is nothing that anybody wants. So is the proliferation of the smooth muscle cell almost protective in a sense, that's one of the things people are starting to think about in calcification, [Alina has these amazing imaging studies, where she looks at matrix vesical accumulation and calcification mitosis. And really the field has noticed, with work by Linda Demer also, the field  has noticed that a large, huge chunk of calcification seems to be much less risky, I guess, compared to the microcalcifications, and I wonder if MIA3 might be like that too, if you can have just enough smooth muscle cell proliferation to kind of keep that cap thicker, is that more protective? Mete Civelek:                   I think that's a really good point that you are raising, because some of the answer is, in that figure 4 in the paper that you mentioned. What we find is that these loci, when people have the risk allele of these loci, so obviously people are at higher risk for coronary artery disease, some of them are associated with higher proliferation, but some of them associated with lower proliferation, same with calcification, same with migration. So it's really difficult to say, at least just looking at the genetic loci, yes, higher proliferation is always better. Cindy St. Hilaire:              Yeah. Mete Civelek:                   There's probably this really delicate balance that allows for plaque stability. Cindy St. Hilaire:              Yeah, it's reminisent, I guess, of the IO1-beta story, right? Mete Civelek:                   Exactly. Cindy St. Hilaire:              Gary Owens and colleagues have really shown that well. The role of it in early versus late plaque is different and it's complicated. That's what we learned. Mete Civelek:                   I agree. And it's specific to MIA3, that locus is also associated with myocardial infarction. Cindy St. Hilaire:              Oh, interesting. Mete Civelek:                   So indeed there is a possibility that really affects plaque stability. Cindy St. Hilaire:              Yeah. So Mete, say you and I are in the same faculty class in that we both started- Mete Civelek:                   Yes we are. We are classmates. Cindy St. Hilaire:              2015 we started our labs, and this is obviously a huge undertaking and really starting a project like this... when you're new, it's really a risk. You're proposing to collect 150 smooth muscle cell lines and characterize them all functionally and it turned out amazingly, but can you maybe talk about the early days in this project's development, and was there ever a moment where you're like, "What the heck am I doing? Is this going to work or..." Just kind of maybe talk to us a bit about that. Mete Civelek:                   That's a really excellent question. To be totally honest with you, I was really lucky to have recruited Redouane to the lab, but he and I worked together when I was a postdoc and when he was a PhD student, as part of this little consortium. So I knew he was going to work hard on his part and he was very driven- Cindy St. Hilaire:              He had magic hands. Mete Civelek:                   And he really want to do this project. So, I knew that it was going to work, but of course he and I both had these moments of, "Are we sure of what we're doing, and why are we doing this? Are we going to get something out of it?" And it was both of us kind of pumping each other, if you will say like, "Yep, this is going to work, we know it's going to work, we have faith in this," but I should also say that my lab also works on adipose tissue biology, and I already had another kind of a safe project going on in that realm. Cindy St. Hilaire:              So, that's funny, I started my lab that way too. I kind of had the project that was the direct continuation of my K grant, and then this kind of high risk, high reward project on valves and you know what, I think that's something that’s smart, it's kind of you have two tracks of research and hopefully one works and then the other one will work. And if they don't work at the same time, hopefully the other one can fill in the gaps, so... Mete Civelek:                   I totally agree with you, but truly, Redouane made a big difference in this project, imagine a postdoc, who's doing nothing but cell culture for two years, hoping that something is going to come out, that's a big risk for him too, it certainly paid off and it's paying off because he has two other papers in the pipeline from this project. Cindy St. Hilaire:              Wonderful. That's excellent. So what's the future for this project? What's kind of the next question you're going to ask if you don't mind sharing. Mete Civelek:                   Oh no, not at all. The most obvious one is looking at gene expression. So we have cultured these cells under two distinct conditions, one is the more contractile phenotype, one is the more productive phenotype. And we did RNA-Seq from, again 150 of these individuals in both conditions and we did what is known as eQTL mapping, so looking at the effect of the genetic loci on gene expression. In a separate project, we also actually collected media from these cells and looked at secreted proteins in the media and we're also finding the genetic loci that are affecting secreted protein, because as you very well know, smooth muscle cells secrete proteins to stabilize plaque stability. So those two papers are Redouane's next projects. And he's almost finished with one and has finished the analysis of the other ones, so hopefully- Cindy St. Hilaire:              That's exciting. Mete Civelek:                   ...more papers coming out in the next six months or so. Oh, I should have said the paper was chosen for the Genomic and Precision Medicine Counci; Young Investigator Award, so Redouane is competing- Cindy St. Hilaire:              Wonderful, also you are in that, excellent. Thank you both so much for joining me today. This was a lovely paper, it was actually inspiring. It made me think about some way to think about my calcification studies. Mete Civelek:                   Thank you so much, Cindy. This was really wonderful. Cindy St. Hilaire:              Absolutely. Thank you. That's it for the highlights from the December 4th issue of Circulation Research. Thank you very much for listening. Please check out the CircRes Facebook page and follow us on Twitter and Instagram with the handle @CircRes and #DiscoverCircRes. Thank you to our guests, Drs Mete Civelek and Redouane Aherrahrou. This podcast is produced by Rebecca McTavish and Ishara Ratnayaka, edited by Melissa Stoner and supported by the editorial team of Circulation Research. Some of the copy texts for highlighted articles is provided by Ruth Williams. I'm your host, Dr Cindy St. Hilaire. And this Discover CircRes, your on the go source, for the most up-to-date and exciting discoveries in basic cardiovascular research.  

In this episode of ASCO eLearning's Social Determinants of Health (SDOH) series, Narjust Duma, MD, moderates a discussion with ASCO CEO, Clifford A. Hudis, MD, FACP, FASCO and Sybil R. Green, JD, RPh, MHA, Director of Strategic Initiatives in ASCO’s Policy and Advocacy Department, on what ASCO is doing as a professional society to address equity as part of its mission.  Subscribe: Apple Podcasts, Google Play | Additional resources: elearning.asco.org | Contact Us   Transcript: PRESENTER: The purpose of this podcast is to educate and inform. This is not a substitute for medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. NARJUST DUMA: Welcome, everybody, to the second episode of ASCO's Social Determinants of Health series. My name is Dr. Narjust Duma. I am an assistant professor at the University of Wisconsin and also a thoracic oncologist. Today I'm joined by ASCO's CEO, Dr. Cliff Hudis, and Sybil Green, Director of Strategic Initiatives in the policy and advocacy department for ASCO. This series is a new initiative proposed by ASCO president, Dr. Lori Pierce. It focuses on increasing oncologists' awareness about the social determinants of health through the cancer care and how impacts our patients' outcome, including modifiable risk factors. This series is inspired by Dr. Pierce's presidential team of equity, every day, every patient, everywhere. In this episode, we look at what ASCO is doing as a professional society to improve health equity and cancer care. Welcome, Dr. Hudis. Welcome, Mrs. Green. First I would like to us what is ASCO doing as an organization in the matter of health equity and cancer care? CLIFF HUDIS: So I guess I'll start here. Thank you very much for spending some time with us on this. If you look at ASCO's mission, it is conquering cancer through research, education, and the promotion of the highest quality and equitable cancer care. So the idea of equity and our responsibility to address disparities is really in our organizational DNA. I have to point out something that many people may not realize. But when ASCO was founded in 1964, one of the seven founders was a black woman, Jane C. Wright. Dr. Wright died in February of 2013. But her father was among the first African-American graduates of the Harvard Medical School. His father was also a physician. And he was educated at what became Meharry. So I remind everybody of this as often as I can, to make the point that not only do we have an opportunity to advance equity and to deal with disparities in health care, but it's my perspective as a leader of ASCO that we have a special obligation and responsibility to do all of that. So we can talk more about it. But I'll just introduce maybe the answer by saying there are really two broad themes at work for us at ASCO. One is externally facing. And one is internally facing. The externally-facing work includes a range of projects and output that we can talk about a little more, but for example our position papers describing disparities and then identifying potential steps to take to address and solve them. But it also includes support for targeted research that is meant to narrow those gaps. It includes our educational efforts, both for our members and for legislators, advocacy for policy, and so on. And then on the internal side-- and here I'll ask Sybil to talk a little bit-- I think we've recently recognized our opportunity, and again responsibility, to think about the workplace itself and to think about our staff and to think about the activities and actions we can take and the roles we can model to create a better world. So I know I've been high level in my initial answer here. But the two domains again are external and internal. And then we can talk about some of the specific projects as we go on. NARJUST DUMA: Mrs. Green, I think it's very important to share about these internal aspects of ASCO because many of us are now aware as members, we see the surface. But ASCO is a large organization with many staff and members. So it would be great that you can share that with us. SYBIL GREEN: Absolutely. And thank you for allowing us to share that. I think Dr. Hudis pointed out some of what we've done since ASCO's establishments and really charging everyone on staff to really live out that obligation of equity, diversity, and inclusion. And so through our programs, our staff have to do their work, make sure that we are creating equitable opportunities for patients and physicians, but it starts at home. And so we have to make sure that internally, we are offering those same opportunities for our staff to engage because what we know is that when staff are engaged, and they have the opportunity to bring their true selves to work every day, they bring their personalities. They bring their lived experiences. And that all plays out in the work that we're doing on behalf of members, in their patients, but also for staff. I think if I were sum up where our program is going, similar to what Dr. Hudis has done, the three components are really enabling staff success. We ought to be able to do that for our staff internally. Every day we ought to provide opportunities for them to succeed. And then making sure that our partnerships-- those that we work with, whether it's in our publications, our meetings-- making sure that our partners goals and ideals align with ASCO's values and ideals. And all of this, of course, is in support of the greater ASCO enterprise, which is our members and the patients and of course, ASCO staff. NARJUST DUMA: And I think that it's really important-- I had the pleasure of interacting with several staff members with diverse backgrounds. And I think as we develop the mentorship program and other things, their input is diverse. It means we also are able to cover the trainees needs because every trainee's needs are different. And because I cannot give a talk or do a podcast without mentioning my grandma, [INAUDIBLE], I have to say that it's important to clean your house first before you go and try to clean other people's houses. I do promise it's beautiful in a Spanish. But I think it's important that everybody knows that internally ASCO is doing a lot of work. And I think it's important to talk about the grants in health equity. And I'm mentioning this because I haven't been doing health equity since I was a med student. And sometimes you find yourself not having enough grant opportunities. Now there is an increase. But when you compare it to other areas of oncology, you may be more competitive because there are less grants. And I think it would be great to hear from the both of you about the new health equity grants, the breast cancer disparity grant, and beyond. CLIFF HUDIS: Well I would just point out something to build on your comment, first of all. Since we were founded in 1964 til now-- so just over 55 years-- we've made unbelievable advances, I think, in oncology in general. Indeed the reason I as an old man chose to go into an oncology in the 1970s was that the vision ahead was that this was going to be an exciting field. And it has not disappointed. However there's a dark that I think we should acknowledge. The advances have not been fairly or evenly distributed. And indeed in some cases when we make massive improvements in outcomes in terms of what's possible with state-of-the-art care, we increase disparities because not every group catches up. And I say all that because it's important to understand that this is not about abstraction. These grants that address that gap are as or more important than the basic science grants that actually advance the biology and understanding in the first place. One without the other is incomplete. So I can't agree more that this is important. And actually from an investment or return on investment point of view, in some ways, these grants are an even better deal because we can rest many of these gaps in care delivery and in knowledge pretty quickly and narrow the gap. And we've seen it. I'm going to give you some examples in a moment. Whereas funding basic science, honestly, is a much higher risk proposition, if you think about it. So I don't mean to set up a false competition here. But I want to point out that there's a big reward. So here's an example. The plenary session abstract at ASCO two years ago now-- abstract number one, if you recall, was no moral less than an analysis of the impact of Medicaid expansion. And what did it show? It showed that with Medicaid expansion, those states that implemented it quickly narrowed the gap in time to initiation of therapy for curable colon cancer. It's a simple take-home point. I care passionately about this personally because these are differences in outcome that have been labeled as associated with race for many years or other specific ethnic facts. But really what they're about is nothing except unfair, uneven access to care in the first place on the basis of race. And it's something that we can address. So we are building out programs to address this through a number of granting mechanisms. For 2020 alone, there are going to be two Young investigator awards that are earmarked for underrepresented populations. And there's a career development award and another YIA, Young Investigator Award, in health disparities specifically. But this is just, I think, part of the issue. The other issue for us-- and actually a commitment going back for years-- is to do something about the workforce itself. And I don't have to tell you, but of course, there is a huge disparity playing out when we look at makeup of medical students in America. And it gets accentuated to the extreme when we look at black men. They are the most disproportionately underrepresented group right now. So how are we going to address that? And we're really proud this year to be launching a program that is aimed at newly-matriculating medical students building on a successful program in Boston that's been running for a couple of years already with Bob Mayer is the founder. And our goal is to the interest of specifically targeted populations, not just in medicine but specifically in oncology. NARJUST DUMA: Mrs. Green, you would like to add something about the grant and what is happening to support health disparities various research at ASCO? SYBIL GREEN: I'll just add the importance of any grant opportunity in any program being one to two. So it's one thing to be able to address bringing in the right medical students to be able to mirror the populations that they serve. It's something else to continue to support them along the way, and so not just stopping at the students, not just stopping at the research, but also making sure that was they're in practice they're supported. And a couple of grants that we've had for some time focus on quality, not just in ensuring that quality services are delivered, but actually helping practices to determine how to identify gaps in [INAUDIBLE] populations that are underserved because we may not be able to identify those same gaps that we would identify in majority populations. And so by giving them the tools to some of the other programs that ASCO has to be able to identify those gaps and then to support them along the way is really important. NARJUST DUMA: And I want to add to what Dr. Hudis mentioned about workforce diversity because this is one of my areas of research and passion. And it's extremely important to have a diverse workforce to represent the patients we're caring for. It's not only having a diverse workforce, but having a workforce that practices cultural humility. We cannot assume that we are proficient or we are competent in somebody's culture. I'm a Latina. And there are so many Latinos in so many different backgrounds that I cannot learn them all. And I think it's important that early interventions are-- because when you get exposed to a specialty early on during the training, that would change your pathway. I'm the daughter of two surgeons. I'm supposed to be a plastic surgeon. But a patient with cancer changed my life and my pathway. So we're able to support those students that have less resources and less access-- and that also includes rural students-- they may don't be black or Latino, they may be white, but they come from rural areas with limited resources-- we are sure that we meet the patient needs because there are aspects I don't understand. Like I'm in Wisconsin, and there are some aspects to farming I didn't know. Now I know when harvest is. And all of that allows us to plan appropriately. So I can see how important it is. And there's a task force that is run by Dr. Winfield, which I'm lucky to be part, that focuses on the workforce diversity. Along those lines, as a minority in medicine, I have seen up and downs of the interest in workforce diversity and health equity. I think many events in 2020 helped a lot of people open their eyes or be more conscious like, oh, that's not isolated. That happens in my back yard. It happened in Kenosha, Wisconsin. But we want to hear how is ASCO making these things long term, how the internal and external changes are going to be long term? And I will start with Mrs. Green and then go to Dr. Hudis. SYBIL GREEN: So in terms of making it long term, it can't be one and done. I think quite often when we focus on equity and diversity issues, we always look at diversity first. And so whether it's workforce or whether it's increasing opportunities for access, you can't just look at the numbers. You have to also think a little bit deeper. You have to think about culture. And so culture with humility, like you mentioned, Dr. Duma, is important, but making sure that attitudes are changing along the way. And that happens through self-awareness. That happens through understanding. And I think that ASCO plays a real role in making sure that our members understand what the issues are and how to dig past those things and provide them with the tools to be able to [INAUDIBLE]. ASCO I think, is not unique. And the idea that this is all new to us has gotten a lot of attention because of some of the social and racial injustice. But what that means is that our members now are probably more interested in ensuring equity than ever before. But we have to teach them how to do it. We have to teach them how to speak the language. We have to teach them how to be more aware, both in their own organizations, at ASCO internally, and for their patients. And so it's a cultural change. It's not going to happen overnight. It's gradual understanding of the dynamics, gradual understanding of different peoples goals, and meeting them where they are, so that we can help them to move along, so that we can come to a more equitable and just [INAUDIBLE]. CLIFF HUDIS: I think one of the things Sybil and I spoke about this summer is we launched our internal EDI effort-- relates to this. And that is this is not about identifying a leaky pipe and patching it and saying, well, we're done now. This is actually, in my view, a permanent change in the way we see work and the way we see our growth. So the goal is to reach a specific landmark. The goal is to change how we think about our work and how we think about our role in the world, so that we're constantly improving. And it's a journey, not a destination, I think, which sounds trite. But that's the spirit of it. And it gets to your question about how we make sure that the commitment is continuous and not just while it's [INAUDIBLE] and exciting. And I think we are committed and dedicated to that. I do want to present a related challenge because it's something you said really sparked this thought for me. As a physician, when did you know that you wanted to be a physician? How old were you? NARJUST DUMA: I was 5. CLIFF HUDIS: And, Sybil, when did you know what your career path was going to be? SYBIL GREEN: I was 9. CLIFF HUDIS: That doesn't support my thesis [LAUGHS] [INAUDIBLE]. So here's the issue. The issue of burnout in medicine right now is getting a lot of attention. And one of the reasons for it, frequently given, is that doctors on average decide to commit to their careers a decade younger than most people on average commit to other careers. You're an exception, Sybil, so I should have pretested the question. But the issue is we're not here to talk about burnout today, even though that's really important. The issue is this. In order to ultimately address the makeup of the population of physicians, we need to reach deeper and further into precollege communities. And we need to show people that they could have lives in science and health care and in medicine and maybe specifically oncology. And I'm just pointing out to you that that's a daunting challenge for a professional society like ASCO. That's not our audience. We don't have a natural connection there. And one of the things that we're working on right now is identifying programs that have worked, that exposed high school students from previously excluded populations or communities to medicine, so that we can spark that passion before college, not during college, and therefore have the commitment that it takes to go far into medicine. And I'll just close by saying something that you hinted at but needs to be said. The reason to have diversity in our workforce is not that an Asian patient needs an Asian doctor. It's that an Asian patient needs a practice that has Asian doctors in it, so that the practice as a whole is able to be culturally sensitive and able to relate and communicate and support them because I think sometimes this issue gets oversimplified as well. SYBIL GREEN: So Dr. Hudis, your theory is not completely [INAUDIBLE] I think it's relevant to this conversation because while I knew what I wanted to do at 9, what I didn't have was the representatives in the community. I didn't have the mentor. Interestingly enough, I had more mentors in pharmacy than I had in law because I saw pharmacists who looked like me. I happened to live in a town where there was a historically black college with [INAUDIBLE]. And so I saw people look like me. And it made it a lot easier for me to reach out to them, for them to mentor me, for them to start talking to me about what equity in health care looked like. That really wasn't until I was in college. But the truth of the matter is for most diverse students, most minority students, that doesn't exist. And I think that that's where ASCO's mentoring programs are really rich. You have the opportunity to do that. NARJUST DUMA: And I think this is important because you can do what you can see. And that has been proven over and over again. We unfortunately are running out of time. But I want to ask the final question. Like a manuscript, like a study, everything has limitations. And I think it's important that we talk about the limitations of ASCO doing this work because realistic expectations are helpful so we don't get disappointed when we have big expectations that may not be met. So Dr. Hudis, what are some of the limitations of ASCO to help equity work now? CLIFF HUDIS: You're right, it's a huge issue. If you think about where our scientific focus is, we can measure the disparities or the difference in outcomes. And we can write a paper about that but when you really get to addressing the reasons for it, it extends far beyond what we can do. So I guess our limit is we can call attention and rally colleagues and collaborate across the House of Medicine and broadly into Congress, where we can make a difference-- or to the United Nations and World Health Organization. But we can't do this heavy lift alone. We need other colleagues who agree who are willing to invest time and money to make the change. SYBIL GREEN: And I would add partnerships because as much as we're talking about social determinants of health, we recognize that all social determinants of health are not health related. They're not [INAUDIBLE]. And many of them live and operate outside of the realm of health care. But what we can do is bring our expertise to the table about the impact of those things, so that our partners stand in their own world, in education, in criminal justice, in financial assistance, how that can help really change the outcomes for patients. I think at ASCO, we've got that expertise. And we can do that. NARJUST DUMA: Thank both of you for your time. Thank you, everybody, for joining us for the second episode of ASCO Social Determinants of Health series. Please keep up with us. You can subscribe. You can see this on Facebook, YouTube-- when it becomes available. We'll continue to explore the social determinants of health and cancer care. You can leave feedback or emails, any questions to the professional development, at asco.org. And I thank you for your time. And have a wonderful week. PRESENTER: Thank you for listening to this week's episode of the ASCO eLearning weekly podcast. To make us part of your weekly routine, click Subscribe. Let us know what you think by leaving a review. For more information, visit the comprehensive eLearning center at elearning.asco.org.

Dr. Rodrigo Quian Quiroga is a Professor and Director of the Centre for Systems Neuroscience at the University of Leicester in the United Kingdom. He is also an author of the books Borges and Memory, Principles of Neural Coding, Imaging Brain Function with EEG, and The Forgetting Machine. Rodrigo is interested in understanding how memory works and how the brain works in general. He conducts experiments to determine how the neurons in our brain make us see, feel, make decisions, and remember the things we experience and learn in our lives. The memory research in Rodrigo’s lab investigates how memories are formed, stored, consolidated, and forgotten. Rodrigo also enjoys getting out of the lab to give his mind a break from thinking about experiments. In particular, he enjoys hanging out with his wife and kids, playing sports, and practicing Judo. Rodrigo received his undergraduate training in physics from the University of Buenos Aires in Argentina and was awarded his PhD in Applied Mathematics from the University of Luebeck in Germany. He was a postdoctoral fellow at the Research Center Juelich in Germany and he received a Sloan Fellowship to conduct research at the California Institute of Technology. Rodrigo also worked briefly at RIKEN in Japan and at the University of Nijmegen in The Netherlands. Rodrigo has received numerous awards and honors including the Royal Society Wolfson Research Merit Award, a Young Investigator Award from the American Epilepsy Society, and Rodrigo was also named one of 10 UK RISE Leaders in Science and Engineering in 2014. Rodrigo spoke with us about his experiences his career, research, and life.

There's been much media speculation and sensationalization around vitamin D and Covid-19 but it's important to remember advice should be evidence based. Vitamin D is essential for good health and low status may be exacerbated during Covid-19 due to increased time spent indoors. A 2018 study identified almost 20% of UK adults have low levels of vit D. In particular, 39% of 11-18 year old girls were deficient. Updated PHE advice in April 2020 advises 10mcg daily even through summer months. People at high risk of vit D deficiency are people whom are frail or housebound and where clothing covers most of skin when outdoors. BUT vit D is just a small part of good health. My guest today is Pf Susan Lanham-New and she's one very busy lady – hugely in demand with her extensive knowledge of vitamin D. Sue has written over 235 publications, is a lecturer on the MSc Nutritional Medicine course which I am close to completing, and is also Head of the Nutrition Science Dept at University of Surrey.  Questions Is vit D necessary? Can we obtain all the vitamin D we need from the sun?  Can vegans rely on D2?   Is 400IU/10mcg enough? Side-effects of high doses? Aside from immunity, why else is vitamin D important e.g. cancer, rickets, osteomalacia? About Susan Professor Susan Lanham-New is head of the Department of Nutritional Sciences at the University of Surrey and is a registered Public Health Nutritionist (RPHNutr). She completed her BSc in Exercise Physiology at the University of Chicester and her MSc in Human Nutrition and Metabolism and PhD in Nutrition and Bone at University of Aberdeen. As a PhD student, Sue was awarded a PhD Scholarship by the Nutritional Consultative Panel, and has three times won the Young Investigator Award at the World Osteoporosis Conference, at the National Osteoporosis Society Conference, and at the Joint Meeting of ECTS and IBMS. Currently, Professor Lanham-New's research focusses on the nutritional aspects of bone health, including specific projects such Interaction between diet and sunlight exposure on vitamin D status in Caucasian and Asian women (D-FINES) study, Extent of vitamin D deficiency in Saudi Arabian women and boys and girls, Impact of veiling on Vitamin D status in Kuwait adolescent girls: impact on bone mass and Protein and bone health: systematic review and meta-analysis. Professor Lanham-New is a member of the Academic Assembly Policy Committee, an Editor-in-Chief of the Nutrition Society Textbook Series and a member of NS Publications Committee.

Goodathleteproject.com For Today's episode we sat down with Timothy E. Hewett, Ph.D.. Dr. Hewett is a former Director of The Biomechanics Laboratories and Sports Medicine Research Center at Mayo Clinic, Director of the Sports Health & Performance Institute at The Ohio State University, Professor and Director of Sports Medicine Research at OSU, and Professor and Director of the Sports Medicine Biodynamics Center at Cincinnati Children's Hospital and Research Foundation. He was a Professor in Sports Medicine, Family Medicine, Orthopaedic Surgery, Physiology and Cell Biology and Biomedical Engineering and Allied Health Professions at The OSU, Pediatrics and Orthopaedic Surgery at the University of Cincinnati College of Medicine, and Professor in Rehabilitation Sciences at the University of Kentucky. Dr. Hewett possesses a doctorate in Physiology and Biophysics and a postdoctoral fellowships in Molecular Biology & Biomechanics, Pharmacolgy and Cell Biophysics and Human Biomechanics. Over four hundred of his research articles have appeared in peer-reviewed medical journals, with over 50,000 citations of his work in the medical literature. Dr. Hewett has an h-index over 113 and his research has received numerous awards, including the Excellence in Research Award, The O'donohue Award and the NCAA Award from the American Orthopaedic Society for Sports Medicine, The Rose Excellence in Research Award from The American Physical Therapy Association, The Research to Reality and Clint Thompson Awards from National Athletic Trainers Associations and the Young Investigator Award from the American Heart Association Dr. Hewett is a Fellow of American College of Sports Medicine and a member of the American Orthopaedic Society for Sports Medicine, the Orthopaedic Research Society & American Physiological Society.

Dr. Anuj R Shah is a Cardiovascular Disease Specialist and the Founder and director of Apex Heart and Vascular Care. He holds multiple board certifications in Cardiology and Interventional Cardiology. Dr. Shah graduated from one of the top universities in India, Gujarat University, in 2003 with six gold medals and honors. He completed a residency and fellowship at University of Connecticut and published numerous articles and abstracts in peer-reviewed journals. He was trained in complex cardiac and vascular cases at Mount Sinai Medical Center in New York. Dr. Shah was selected for The Young Investigator Award from American Society of Nuclear Cardiology and has spoken at several national cardiology conferences on cardiogenic shock. Dr. Shah has held leadership positions including Director of Vascular Interventions at Good Samaritan Hospital and Bon Secours Hospital in NY. He also served as the Assistant Professor of Medicine at The Mount Sinai Medical Center. Dr. Shah currently has hospital privileges and performs interventional procedures at The Hackensack University Medical Center, St. Mary’s Medical Center and St. Michaels Medical Center. He specializes in the treatment of circulatory disease, treatment of varicose veins, swelling of the legs, and venous ulcers. Dr. Shah was the past President of the Bergen Indian Medical Association. For more information on Dr. Shah, visit http://www.apexheartandvascular.com

Join host, Dr. Shannon O'Connor, as she interviews Dr. Alexander N. Shoushtari. Dr. Alexander Shoushtari is an Assistant Attending Physician and Clinical Director of the Melanoma Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medical College. He focuses exclusively on treating patients with melanoma using standard and developmental immune and targeted therapies. Within melanoma, his specific interests lie in developing treatments for non-cutaneous melanoma subtypes arising from the uveal tract in the eye, hands/feet, and mucosal surfaces. His early career work in uveal melanoma systemic therapy has been recognized by ASCO with a Young Investigator Award and AACR with a Junior Investigator Award.Tune in while Dr. Shoushtari and Dr. O'Connor discuss cancer treatment in the era of COVID along with Dr. Shoushtari's current research at Memorial Sloan Kettering Cancer Center.

Dr. David S. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong received a bachelor’s degree in biology from Yale University and a medical degree from Albert Einstein College of Medicine. He then completed an internship and residency at Thomas Jefferson University Hospital and a medical oncology fellowship at MD Anderson, during which time he was appointed chief medical oncology fellow. In 2005, he joined MD Anderson’s faculty. Dr. Hong is the recipient of the 2004 Young Investigator Award from the American Society of Clinical Oncology, the Jesse H. Jones Fellowship in Cancer Education, MD Anderson’s Best Boss Award, the Irwin H. Krakoff Award for Excellence in Clinical Research, the Gerald P. Bodey Award for Excellence in Education and a research training fellowship from Howard Hughes Medical Institute. He has published more than 270 articles in prestigious journals. John Marchica is a veteran health care strategist and COO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest-growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University and is an active member of the American College of Healthcare Executives. About Darwin Research Group   Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Dr. Hayes interviews Dr. Mayer on his training at NCI and running DFCI’s fellowship.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Welcome to JCO's Cancer Stories-- The Art of Oncology, brought to you by the ASCO podcast network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the role of cancer care. You can find all of these shows, including this one, at podcast.asco.org. Today, my guest on this podcast is Dr. Robert J. Mayer. Dr. Mayer is the Stephen B. Kay Family Professor of Medicine at Harvard Medical School where he is also the Faculty Associate Dean of Admissions, in addition, the faculty Vice President for Academic Affairs for Medical Oncology at the Dana-Farber Cancer Institute. Dr. Mayer was raised in Jamaica, New York. And, Bob, I always thought you were raised in Brooklyn, but I looked it up on the map. And it looks like Jamaica is about two blocks in the middle of Brooklyn. So we'll say you're from Jamaica. Actually, I was a little bit to the east of there in Nassau County. That counted a lot then, Queens versus Nassau, but anyway. So it gets even more esoteric. Bob received his undergraduate degree in 1965 from Williams College, which is way out west in Massachusetts, and then went to Harvard where he got his MD in 1969. He did his residency in internal medicine at Mount Sinai in New York City and then was a clinical associate in the medicine branch of the National Cancer Institute from 1971 to 1974. He served a fellowship in medical oncology at what was then the Sidney Farber Cancer Institute. And then he joined the faculty in 1975. He has spent much of his career at leading clinical research in leukemia and GI malignancies. He was the chair of the CALGB, now called the Alliance TI Cancer Committee for years. But, perhaps more importantly, he was director of the fellowship program at, originally, the Sidney Farber and then the Dana-Farber Cancer Institute for 36 years. And then he was also head of the fellowship program at the Dana-Farber/Partners cancer program from 1995 until 2011. And, frankly, he was my fellowship director from 1982 to 1985. So I owe a great part of my career to Dr. Mayer. He's co-authored over 400 peer-reviewed papers and another 130 chapters and reviews. He serves as associate editor for both the Journal of Clinical Oncology and The New England Journal of Medicine. And, as have many guests on this program, he served as president of ASCO, in his case, in 1997, 1998. And he received the ASCO Distinguished Achievement Award in 2019 for his ongoing leadership in our society. Dr. Mayer, welcome to our program. Pleasure to be with you, Dan. So I have a lot of questions. And, again, I usually do this, you know, two guys in a cab. How did you do that in the first place? What got you interested in oncology coming out of Williams and at Harvard? And, at that time, there wasn't much in oncology. What made you want to take care of cancer patients? Well, I was a third-year medical student at Harvard sort of sleepwalking through the curriculum, undecided what my life was going to be, planning to go back to New York, and I came across an attending physician on a pediatrics rotation, a hematologist by the name of David Nathan. And we hit it off. And I became really interested in blood cells and how looking at smears and bone marrow morphology could tell you a lot about the status and health and nutrition of individual patients. Nathan took a shine to me. And, when I was a fourth-year student and was going to face probably a military service, and there were military actions going on in Southeast Asia, he called me to his home one night and shoved a whole pile of paper in front of me, said fill this out. I want it back tomorrow. And this was an application to be a clinical associate at the National Cancer Institute where he had spent several years I guess a decade before. So I did what I was told. And, when I was a intern, I guess my first day as an intern, I got an overhead page from the-- in the hospital, call from Bethesda informing me that I had been accepted. I had had 10 or 11 interviews. One of them turned out to be a person who would be important in my life as a friend and a mentor, George Canellos, who was first time I met him. And, in 1971, I found myself at the NIH. That's quite a story. And Dr. Nathan, of course, went on to start the Jimmy Fund, probably had already started the Jimmy Fund Clinic at the time, and became the CEO, I think, of Children's Hospital in Boston. He became the CEO of Dana-Farber actually. I do want to just recollect with you my first day or two in Bethesda because some of the people who found themselves there took it more seriously than others. And I was assigned to the medicine branch. And the medicine branch had a chief who was a breast cancer-oriented investigator by the name of Paul Carbone who went on from there to an illustrious career as the founding head of the Cancer Center at the University of Wisconsin and the leader of the Eastern Cooperative Oncology Group. And Paul, at that point, the first day I met him, told us that, if we messed around, moonlighted, didn't show up, we'd be on a Coast Guard Cutter as fast as he could do the paperwork because, technically, we had a position in the Public Health Service. Under Carbone, there were two branches. One was leukemia, and that was headed by Ed Henderson. He was a lanky guy from California, a wonderful man, went on to a career with Cancer and Leukemia Group B and with the Roswell Park in Buffalo for many years. And he was my branch chief. And the other branch was solid tumors. They weren't solid tumors like we think of them today. They were lymphomas. And that was headed by Vince DeVita and had Bob Young, George Canellos, Bruce Chabner, and Phil Schein, all illustrious founders of so much that has become oncology. So that was the setting. And the last thing I'll mention was about this. I came there as a trained internist, but I was assigned to pediatric leukemia. And I learned very quickly that what separated the wheat from the chaff, in terms of families, parents thinking that you were a good doctor, was your ability to maintain the 25 gauge scalp vein as venous access in these children because there were no port-a-caths, no Hickman lines, and, obviously, access was something that was critically important. You know, I think everybody who is listening to this needs to understand that what you just described started out really with just Gordon Zubrod who then brought in Frei, Holland-- or Holland first and then Freireich. And then they brought in the next group, which I believe you would agree is Canellos, DeVita, Bob Young, and others. And then you were sort of in the third wave. And you could just see it began to expand the whole field of oncology really just from a few people going out. Do you agree with that? I do. I do. When I came to the NIH in 1971, there was no defined, certified subspecialty of medical oncology. The first time the medical oncology board examination was given was in 1973. It was given every other year. I was in the group that took it the second time in 1975, but this really wasn't a subspecialty. In 1973 also was the time that the first comprehensive multi-authored textbook on medical oncology was published by Jim Holland and Tom Frei, Cancer Medicine. And I remember devouring that as I prepared for the board examination, but there was no book like that. There was no reference, no UpToDate, no computer to surf the web and find information. And so this was all brand new. It was quite exciting to be there as part of the action. You sort of jumped ahead on what I wanted to ask you, but I'm interested in the establishment of medical oncology as a subspecialty. Can you maybe talk about Dr. BJ Kennedy and his role in that? I think he was pretty instrumental. Was he not? BJ was at the University of Minnesota. He was an extraordinarily decent man. And, somehow, the internal medicine establishment viewed him as a peer and a colleague, which I would have to say was not what they considered many of the pioneers, if you will, in medical oncology. I can remember, in my second or third year at the NIH, traveling around the country to look at fellowship programs. And I was always being met by senior established hematologists who arched their eyebrows and said now where's the pathophysiology. Where is the science here? They really thought that the animal models, the mouse models, the Southern Research Institute that Gordon Zubrod had been such a pioneer in fostering was pseudoscience. I can also remember, when I found myself back in Boston, the establishment of Harvard Medical School didn't initially take oncology very seriously, but there were patients. And there was optimism. And all of us in that generation really believed that we could make a difference, and we could learn a lot and do good for patients and for medicine. And I think we have. So, in my opinion, now, appropriately, our fellows have a very strict curriculum of what they're supposed to learn and how and when and why laid out, again, in a pretty rigorous formal manner. You told me before, at the NCI, it was just sort of learn it. It's up to you. Can you talk about that training? And then, when you went to the Sidney Farber, you then turned that into a training program. The medicine branch was fantastic training, but it was learning from taking care of patients and from your colleagues. The quality of my peers was extraordinary, but there was no formal curriculum. The faculty there each were doing research, the members of the faculty. And, for a month, they would come out of their cave, if you will, their laboratory, and they were very smart and were doing fascinating things, but they didn't have long-term patients. Or there was no real process. And the NCI was sort of like a Veterans Administration hospital in the sense that it opened around 7:30 or 8:00 in the morning, closed at 5:00 or 6:00 in the afternoon. One of us would be on call at night with a couple of nurses, but it was rather primitive in its support mechanisms. We were assigned a group of patients. And then, on rotation, those patient numbers would increase. And we were expected to do everything conceivable for that patient. And, at that time, the oncology care offered in Bethesda at the NIH or the NCI was free. It was paid for by the government. And much similar care was not available in other places. So I would have patients flying in from Omaha and New York or Norfolk or Tampa, Florida. And they would be housed in a motel that was on the edge of the NIH reservation, but, if one wants to talk about continuity of care, you knew everything about every one of those patients because you were the only person who knew them. So what were the circumstances then that you ended up in Boston? Well, that's an interesting story because it gets back to David Nathan. I was working after my clinical year in a basic laboratory as I could find. It was run by Robert Gallo, Bob Gallo, who was one of the co-discoverers years later of the HIV virus. But, one day, I got a phone call from Dr. Nathan's secretary saying that he was going to be in Washington a week from Tuesday or whatever. And he wanted to meet with me in the garden of the Mayflower Hotel. OK, fine. So I trotted over to the Mayflower Hotel, and there was Dr. Nathan. And he said, you know, Dr. Farber is getting old, but there's a new building. And there's going to be a cancer center. And he's just recruited Tom Frei to come from MD Anderson. And it's time for you to come back to Boston. Didn't say would you like to come back, would you think about coming. No, he, just applied to the NIH, shoved the papers. Here, it's time for you to come back to Boston. So, a few Saturdays after, I flew up to Boston. And, in that interim, Dr. Farber passed away. He had a heart attack, an MI. And there was Tom Frei who I met for the first time, made rounds with him. We hit it off. And he told me that he would like me to spend one year as a fellow and then join the faculty and become an assistant professor. Well, I didn't need a plane to fly back to Washington. I thought this was tremendous because I was looking at hematology scholarships around the country. And there was no career path. And this seemed to be a career path in a field that I was really interested in. And he talked to me really about coming back to do leukemia because that's what I had been doing at the NIH. And, a year later, I found myself, July 1, 1974, being part of the second fellowship class at what's now Dana-Farber. There were six of us. There were six the year before. We were piecing it together step by step. There, again, was nothing chiseled in marble. There was no tradition. This was try to make it work and learn from what works. And, what doesn't work, we'll change. You must have had a lot of insecurity coming into a program that really had just started. There had to be chaos involved in that. Well, there was a little chaos, but, to be honest, I was really engaged in it because it was exciting. I thought that oncology, as I still do, is this marvelous specialty or subspecialty that unites science and humanism. And, because other people weren't interested or maybe weren't capable of providing what we thought was the right level of care, to be able to sort of write the playbook was a terrific opportunity. We sort of-- and it extended into the year that you were a fellow as well-- followed the medicine branch mantra in the sense that we assigned fellows patients. And they took care of those patients and were expected to do everything that was necessary for them. There weren't rotations at that time that you would spend a month on the breast cancer service and then a month doing lymphoma. You would see new patients or follow-up patients. We didn't really have enough patients or enough faculty at that point to be smart enough to think about that being a better way or an alternative way to structure a trainee's time. I remember, at the end of my first year, when I finished that year as what I think Tom Frei called a special fellow, I was the attending on the next day, which was July 1. And I remember that a fellow, a first-year fellow who was just starting, Bob Comis who became also the chairman of the Eastern Cooperative Oncology Group years later, a marvelous lung cancer investigator, was the trainee. And, on that day, we went ahead and did a bone marrow on a patient with small cell lung cancer and being a fellowship director just started because there was no one doing it. And Frei said please move ahead. I have to say, when I started in 1982, I just assumed this was the way everybody in the country was training fellows in oncology. It really didn't occur to me that that was only a few years old and the way you had set it up. A few years ago, the Dana-Farber had a banquet to celebrate the 48-year career of a guy named Robert J. Mayer. And I was asked to speak. And I got up. There were over 300 people in the audience, all of whom had been trained there. And, as I looked around, I sort of put my prepared words aside and said look at the people sitting next to you. They are either former or to be presidents of ASCO, ACR. They're cancer center directors, department chairs, division chiefs, and a bunch of really terrifically trained oncologists all due to one guy, and you're the one. So you started with Bob Comis-- I've never heard you tell that story-- to really training some of the greatest oncologists in the world in my opinion, myself excluded in that regard, but, nonetheless, you must be quite proud of that. Well, yes, but I want to flip it around the other way because, for me, this became a career highlight, the opportunity to shape the patterns, to make the people who trained here leaders, and to have them-- right now, the director of the NCI is a Dana-Farber alumnus. To have people who are of that quality-- and you certainly represent that, as an ASCO president and one of the hallmark leaders of the breast cancer community-- this is what a place like Dana-Farber and Harvard Medical School, hopefully, not too much arrogance, is supposed to be doing. And to have that opportunity, to be able to fill a vacancy that nobody even appreciated was a vacancy, and then to develop it over enough time that one could really see what worked and see what didn't work is an opportunity that most people don't have. And I'm so grateful for it. Now, Bob, I want to just, in the last few minutes here, you've obviously been a major player in ASCO. Can you kind of reflect over the last 25 years since you were ASCO president, the changes you've seen, and what you think of your legacy? I know you don't like to brag too much, but I think there's a reason you got the Distinguished Service Award. And can you just reminisce a bit about what's happened and then where you think we're going as a field? Well, ASCO has been my professional organization. The first meeting I went to was in a hotel ballroom in Houston, the Rice Hotel, which doesn't exist anymore. And it was a joint meeting of ACR and ASCO in 1974. There were 250 people. And everybody was congratulating each other at the large number of attendees. I had the opportunity, in large part because of Tom Frei and George Canellos and other people, to become involved in picking abstracts for leukemia presentations, being part of the training committee, and then chairing the training committee. I actually had the opportunity to be one of the four people who started the awards program, which now has the Young Investigator Award and Career Development Award and things of that sort. These are just opportunities because they weren't there before. And, if you're willing, and you put in the time, I guess people come back to you and give you the chance to do these things. I became then involved in the JCO, the Journal of Clinical Oncology. I became involved in the debate about physician-assisted suicide and palliative care that led to some very educational debates and probably spawned the field, to some degree, of palliative care. I had the opportunity to be at the forefront of starting the Leadership Development Program that was really Allen Lichter's idea, but I was able to devote the time to make that happen. And, most recently, I've been on the Conquer Cancer Foundation now for almost two decades. And watching that grow has been a joy. ASCO, when I came, was a very small trade organization, if you will, didn't quite know the questions to ask, had a hired office, a management office, that was based in Chicago, came to Alexandria in about 1994 or somewhere in that range with its own office and its own staff, and now is the world organization for oncology. And I think that that growth, that expansion, that international, multidisciplinary pattern, if you will, is a reflection of the growth of oncology in medicine. I have to say, if you take a look at the popularity poll of what the best and the brightest young physicians choose in their careers, when I was in training and, Dan, when you were in training, most went into cardiology. Maybe some went into GI. Now there are more people going into oncology than any other medical subspecialty. Maybe that'll change after COVID, but that's the way it's been. And our hospitals now are filled with cancer patients, and those hospitals are very dependent on the care that we provide cancer patients. I guess the other thing I would say is, looking from a guy with some hair left, although gray, but looking at it from afar, all of those high-dose chemotherapy programs, the notion of dose, of cell poisons, alkylating agents, the solid tumor autologous marrow programs that were so fashionable in the 1980s, have been, in large part, replaced by such elegant, targeted therapy, now immunotherapy, circulating DNA. Who would have thunk any of that when I was taking care of those children with leukemia 45 years ago? So I think this is such an exciting field. I'm so-- continue to be so pleased and proud of the quality of the trainees. Last night, we had a virtual graduation session for the people completing their fellowship here. And I hate to say it. They're as good as ever. And, if we thought and, Dan, if you thought your colleagues that you all and we all were the best, they're all phenomenal. And it's really a reflection on how the pioneers in this field had a vision, how the need for science to understand cancer was so important, and how medicine has changed and how oncology now is a respected and acknowledged discipline of scholarly work. Well, you had two things that I'm fond of commenting on. One of those is I frequently say publicly I wish I was 30 years younger for a lot of reasons, but because of the scientific excitement that's going into oncology and, also, so that I could run the way I used to, but I can't. That's one. The second is I don't think I would choose me to be a fellow. I'm really intimidated when I do interviews with our residents and say, you know, I wasn't nearly in that kind of category of the people we're interviewing now, which is great. I think our field is in good hands, going to move forward, and things are going. Bob, we've talked about a lot of your contributions to training and education, but you've also had a major influence on the way patients with leukemia are treated. Can you talk more about where the 7 and 3 regimen came from? The 7 and 3 or 3 and 7 regimen-- 3 days of an anthracycline, 7 days of continuous infusional cytosine arabinoside, was developed in the early 1970s. And it was developed by Jim Holland, more than anyone else, when he was at Roswell Park. And it emerged from a series of randomized, phase III trials conducted by what was then called the Acute Leukemia Group B, what became CALGB and then the Alliance. In the early 1980s, the late Clara Bloomfield, who I considered a giant in the world of leukemia, invited me to write a review of the treatment of acute myeloid leukemia for seminars in oncology that she was editing. And, in preparing that, I started reading a series of manuscripts published in the early 1970s, which meticulously, step by step, examined the value of two versus three days of anthracycline subq versus IV push versus infusional cytosine arabinoside, 3 days, 5 days, 7 days, 10 days of infusional cytosine arabinoside. And this was all really work of Jim Holland. He was a magnificent scholar, a humanist, and a tremendous booster too and giant in the start of this field. Thank you. I agree. Bob, we've run out of time, but I want to just thank you for taking time today to speak to me and our listeners, but also thank you for what I consider the many contributions you've made, both scientifically-- we didn't really even get into that, your work on leukemia and GI-- but I think, more importantly, establishing a training program that's been the model for, probably worldwide, how to train people in oncology and the contributions you've made to ASCO. So, for all that, I and everybody else are very appreciative. Thanks a lot. My pleasure. It's a pleasure to be here with you. Until next time, thank you for listening to this JCO's Cancer Stories-- The Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories-- The Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org.

Dr. Martha Muñoz is an Assistant Professor in the Department of Ecology and Evolutionary Biology at Yale University. Martha is an evolutionary biologist who is working to better understand how and why evolution proceeds unevenly across the tree of life. Some features and branches or organisms are evolving really quickly, while others remain inert or nearly inert for millions of years. Her research is uncovering the mechanisms underlying this phenomenon. For Martha, nature is a wonderful source of peace and inspiration for her research. When she’s not working, she enjoys exploring the outdoors, hiking, seeing amazing views, and observing wildlife. She also spends her free time reading, going to museums, and visiting her family in New York City. She received her B.A. in biology from Boston University. Afterwards, Martha worked as a Fulbright Research Scholar at the National Museum of Natural Sciences in Madrid, Spain. She was awarded her Ph.D. in Organismic & Evolutionary Biology from Harvard University. Next, Martha conducted postdoctoral research in the Research School of Biology at The Australian National University and subsequently the Department of Biology at Duke University. Prior to accepting her current position at Yale University, Martha served on the faculty in the Department of Biological Sciences at Virginia Tech. Martha has received numerous awards and honors, including the Boston University Department of Biology’s Distinguished Alumni ‘Rising Star’ Award, and a Young Investigator Award from the American Society of Naturalists. She was also named a ‘Scientist to Watch’ by The Scientist Magazine in 2019. In our interview, Martha will tell us more about her life and science.

Set against the growing interest in supplements which has been heightened by the Covid-19 pandemic, this podcast will look at what role nutraceuticals and supplements might play in boosting immunity and the potential benefits this could bring to the health system. What is the science behind nutraceuticals and supplements boosting immunity? What is the right advice to give to consumers and what role can industry play? Do nutraceuticals and supplements act as a good resource for boosting immunity? We explore the science behind the headlines and how industry, academia and policy makers can work together to deliver the right solutions that will help consumers and potentially benefit the wider public health agenda and system. About our panel Professor Mairead Kiely, Professor of Human Nutrition and Head, School of Food and Nutritional Sciences, University College Cork (https://www.ucc.ie/en/) Mairead is co-chair of the Cork Centre for Vitamin D and Nutrition Research at UCC and led a Pan-EU project on vitamin D requirements, food fortification and health outcomes until early 2018. She leads the Maternal and Child Nutrition Programme at the INFANT Research Centre. Mairead has more than 25 years experience in human nutrition and health research and she has worked on vitamins, minerals and bioactive food constituents throughout her career. She is a registered public health nutritionist with the Association for Nutrition and is currently the chair of the Irish Section of the Nutrition Society. Professor Susan Lanham-New, Head of the Department of Nutritional Sciences, University of Surrey Professor Susan Lanham-New is head of the Department of Nutritional Sciences at the University of Surrey and is a registered Public Health Nutritionist (RPHNutr). She completed her BSc in Exercise Physiology at the University of Chicester and her MSc in Human Nutrition and Metabolism and PhD in Nutrition and Bone at University of Aberdeen. As a PhD student, Sue was awarded a PhD Scholarship by the Nutritional Consultative Panel, and has three times won the Young Investigator Award at the World Osteoporosis Conference, at the National Osteoporosis Society Conference, and at the Joint Meeting of ECTS and IBMS. Currently, Professor Lanham-New’s research focusses on the nutritional aspects of bone health, including specific projects such Interaction between diet and sunlight exposure on vitamin D status in Caucasian and Asian women (D-FINES) study, Extent of vitamin D deficiency in Saudi Arabian women and boys and girls, Impact of veiling on Vitamin D status in Kuwait adolescent girls: impact on bone mass and Protein and bone health: systematic review and meta-analysis. Professor Lanham-New is a member of the Academic Assembly Policy Committee, an Editor-in-Chief of the Nutrition Society Textbook Series and a member of NS Publications Committee. Professor Judith Buttriss, Director General, The British Nutrition Foundation Judy studied Nutrition and Dietetics at the University of Surrey. She worked as a research dietitian in Professor John Waterlow’s obesity unit for about a year before returning to Surrey to study for a PhD concerning vitamin C and hepatic drug metabolism, which combined the disciplines of nutrition, biochemistry and toxicology. Equipped with a doctorate, Judy worked in various labs as a postdoc researcher, in particular on vitamin E and selenium at Guy’s Hospital Medical School. In 1985 she decided to leave the lab environment and joined the National Dairy Council (NDC) as Senior Nutritionist, where she stayed until 1998 when she joined the BNF as Science Director. She became the BNF’s Director General in October 2007. Rob Hobson, Nutrition Consultant As a registered nutritionist (Association for Nutrition), Rob's worked with many of the UK’s largest food and health companies and with training in public health (MSc public health nutrition). He also works with organisations including schools, care homes, government agencies and the NHS. With over a decade of work experience in the field of nutrition, Rob has also established an impressive network of health media and those working in the food and health industry including nutritionists, chefs, personal trainers and PR that have proven to be an invaluable resource.

Asmeret Asefaw Berhe is a Professor of Soil Biogeochemistry at the Life and Environmental Sciences unit, University of California, Merced. She received her PhD in Biogeochemistry from the University of California, Berkeley; M. Sc. in Political Ecology from Michigan State University, and BS in Soil and Water Conservation from University of Asmara, Eritrea. She is a recipient of numerous awards including the National Science Foundation’s CAREER award, the Young Investigator Award from Sigma Xi, and the Hellman Family Foundations award for early career faculty. Basically, she rocks. Her research focuses on biogeochemical cycling of essential elements (esp. carbon and nitrogen), in particular in systems that experience physical perturbations (ex. erosion, fire, changes in climate). At the AAAS 2019 annual meeting in Seattle, we had a chance to sit down with her for a live interview where we talked about soil (not dirt), bribing lab mates to help with experiments, looking to the ground to mitigate climate change, and more! This episode was produced by and mixed by Shane M Hanlon.

Dr. Simon Sponberg is Dunn Family Professor and Assistant Professor in the School of Physics and the School of Biological Sciences, as well as Adjunct Assistant Professor in Biomedical Engineering at the Georgia Institute of Technology (Georgia Tech). Through his research, Simon is interested in understanding how the brain works with muscles to make bodies move. Animals move gracefully in nearly all environments on Earth, and many types of movement can be difficult to perform in robotics and other created systems. Simon uses animal models to study how the body and the muscles inform the brain in terms of the information we take in and how we react to the environment. He received his B.A. in physics and biology from Lewis & Clark College and his Ph.D. in Integrative Biology from the University of California, Berkeley. Afterwards, Simon conducted postdoctoral research at the University of Washington before joining the faculty at Georgia Tech. He has been the recipient of an NSF Postdoctoral Fellowship in Biological Informatics, the University of Washington Postdoctoral Mentoring Award, the Young Investigator Award from the International Society for Neuroethology, an NSF Faculty Early Career Development (CAREER) Award, a Klingenstein-Simons Fellowship in the Neurosciences, and a Hertz Fellowship. In our interview, Simon shares more about his life and science.

Dr. Anuj R Shah is a Cardiovascular Disease Specialist and the Founder and director of Apex Heart and Vascular Care. He holds seven board certifications in Cardiology and Interventional Cardiology.  Dr. Shah graduated from one of the top universities in India, Gujarat University, in 2003 with six gold medals and honors.  He completed a residency and fellowship at University of Connecticut and published more than 50 articles and abstracts in peer-reviewed journals. He was trained in complex cardiac and vascular cases at Mount Sinai Medical Center in New York.  Dr. Shah won The Young Investigator Award from American Society of Nuclear Cardiology and has spoken at several national cardiology conferences on cardiogenic shock. Dr. Shah has held leadership positions including Director of Vascular Interventions at Good Samaritan Hospital and Bon Secours Hospital in NY.  He also served as the Assistant Professor of Medicine at The Mount Sinai Medical Center.  Dr. Shah currently has hospital privileges and performs interventional procedures at The Hackensack University Medical Center, St. Mary’s Medical Center, St. Michaels Medical Center, and Englewood Hospital. He specializes in treatment of circulatory disease, treatment of varicose veins, swelling of the legs, and venous ulcers.  Dr. Shah holds seven board certifications in Coronary and peripheral vascular interventions, Level II Echocardiography, Level II Nuclear Cardiology, Level II Vascular Ultrasound Interpretation, Level II Coronary CT Angiography and ABI/PVR Analysis.  Dr. Shah is the President of Bergen Indian Medical Association. Dr. Shah has been named a “Top Physician” in the 2015 edition of Leading Physician of the World and has been among the “Top Doctors of New Jersey” since 2015. He was recently featured on Healthline on Artificial Intelligence and AFIB. For more information on Dr. Shah, visit http://www.apexheartandvascular.com

The NCS Podcast Series - News Flash covers new science in neurocritical care.  ​ ​For the first time, the NCS Podcast is recording directly from the NCS Annual Meeting! For real time updates follow #NCS2019 In this episode, Dr. Benjamin Miller interviews the 2019 NCS Annual Meeting winner of the Cristanne Wijman Young Investigator Award – Erta Beqiri, MD for her abstract titled "Individualizing Cerebral Perfusion Pressure Using the Lower Limit of Reactivity: A CENTER-TBI High-Resolution Sub-study Analysis." The NCS Podcast is the official podcast of the Neurocritical Care Society. Our senior producer is Bonnie Rossow. Our host is Fawaz Almufti, and our production staff includes Ramani Balu, Michael Brogan, Joshua Levine, Sarah Stern-Nezer, Benjamin Miller, Starane Shepherd, and Chris Zammit. Our administrative staff include Becca Stickney, Sara Memmen, and Angel Gindele.

ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. The 2019 World Conference on Lung Cancer was held September 7 to 10 in Barcelona, Spain. In this podcast, Dr. Vamsidhar Velcheti will discuss a study presented at this meeting that looked at the effects of a new drug targeting a specific genetic change, or mutation, in some people with non-small cell lung cancer. Dr. Velcheti is Associate Professor and Director of Thoracic Medical Oncology at NYU Langone’s Perlmutter Cancer Center. He is a member of the Cancer.Net Editorial Board and is also the recipient of a 2012 Young Investigator Award and a 2015 Career Development Award from Conquer Cancer, the ASCO Foundation. Dr. Velcheti has no relationships to disclose related to this drug. ASCO would like to thank Dr. Velcheti for discussing this topic. Dr. Velcheti: Hi. This is Vamsi Velcheti. I'm the director for the Thoracic Medical Oncology Program at NYU Langone Hospital. And it's my pleasure to discuss an abstract presented at the World Lung Cancer Conference in 2019 in Barcelona. And the abstract I'd like to discuss is treatment with Amgen 510, Amgen five, one, zero, which is a highly selective potent KRAS G12C inhibitor. This was the data presented by Dr.  Ramaswamy Govindan at the World Lung Cancer Conference in Barcelona in 2019. So KRAS G12C appear as mutations in lung cancer are the most common driver oncogenic mutations. And, in fact, KRAS G12C was one of the first driver oncogenic mutations that was identified in non-small cell lung cancer. However, despite our several efforts to target KRAS G12C with multiple different drugs, we have failed to develop an effective targeted therapy option for patients with KRAS mutations. And this is very much unlike other mutations like EGFR, ELK, ROS, RET. So these mutations have a lot of treatment options for patients with targeted therapy. But unfortunately, that's not the case for KRAS mutation positive lung cancer patients. And KRAS G12C inhibitors like for Amgen 510 have showed us a way forward in terms of developing more effective targeted therapy treatments. So this abstract presented by Dr. Ramaswamy Govindan at World Lung Cancer Conference is a fierce one, the trial of AMG 510. And in this study, they enrolled all types of solid tumors and predominantly colorectal cancer and lung cancer patients with a specific subtype of KRAS mutations called KRAS G12C. That is a KRAS mutation in the code on G12C. And in this study, they have seen very promising activity, anti-tumor activity in patients with non-small cell lung cancer, especially harboring KRAS G12C mutations. So out of the 76 patients that are enrolled in the study, 34 patients were patients with non-small cell lung cancer harboring KRAS G12C mutations. And out of these 34 patients, there were patients treated in the dose escalation part of the phase I study, meaning they were evaluating the safety of the drug at low doses, and they were escalating the dose in the patient. And there were 15 patients in the study that were treated at the maximum dose that was planned. For the study, which was the 960 milligram dose. So out of our 34 patients that were enrolled in the study, 34 patients with non-small cell lung cancer, most of the patients were heavily pretreated with at least 2 lines of prior treatments. And they were refractory to prior treatments. So after 34 patients treated with AMG 510, nearly half of the patients had a partial response to treatment. And this is a significant advancement in terms of targeted therapy for KRAS mutant lung cancers. In previous studies with other agents, we have not seen such dramatic responses. And a majority of these responses have been confirmed responses. And the study is very early, and the data presented so far was only from the phase I trial. And there are more patients being enrolled in the ongoing phase II trial with the Amgen 510 in patients with KRAS G12C mutations. And most importantly, this drug seems to be fairly well tolerated and with relatively few treatment-related adverse events. And most of the adverse events were like a grade 1 and 1, with the most common adverse events being diarrhea, nausea, and 1 case of anemia, but has a substantially better safety profile than most other chemotherapy options for patients. So this is a very encouraging study. And we are all looking forward to more of these drugs targeting KRAS G12C and certainly excited to see these early results. And hopefully we'll see more further validation of these exciting early findings in subsequent phase II trials. Thank you very much. ASCO: Thank you, Dr. Velcheti. Learn more about lung cancer at www.cancer.net/lung. And if this podcast was useful, please take a minute to subscribe, rate, and review the show on Apple Podcasts or Google Play. This Cancer.Net podcast is part of the ASCO Podcast Network, a collection of 9 programs covering a range of educational and scientific content offering insight into the world of cancer care. We’re interested in your opinions about your preferred podcast format and content offerings, so we hope you’ll take a few minutes to take our listener survey. Visit podcast.asco.org to find a link to the survey and help shape the future of the ASCO Podcast Network. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/support.

Sleep specialist Dr Sabrina Skorski joins us on the show today to stress the importance of sleep for athletes and anyone who wants to perform at their peak.   Based in Germany, Sabrina is a degree coordinator of international Master of science and high performance at the University of Saarland.   With over 25 publications and winner of the Young Investigator Award at the Aspire Sport Science Conference, Sabrina takes time out of her busy schedule to emphasise the need for pushing out zzz’s, but this episode certainly won’t send you to sleep. Please enjoy.   Sponsorship Info This episode is proudly brought to you by Stick Mobility. The Stick Mobility system can be adapted to suit all activity levels making it an extremely versatile and valuable addition to anyone’s training.  Stick Mobility is “Movement made better”.  To learn more and book into the next course, head to stickmobility.com.au. The first 10 sign ups using the reference ‘TSWSPodcast’ will receive 10% off the registration cost for the course!   This episode is also brought to you by Blackroll. Receive 15% your recovery pillow using the code 'TSWS15' at payment. For Australian customers, receive 15% off all Blackroll products on www.blackroll.com.au with the same discount code.   Team Contact Email us at team@tswspodcast.com for guest recommendations or any questions you want answered about previous guests or research we’ve discussed. Guest Details If you'd like to learn more or get in touch with Sabrina, please follow the links below: https://www.linkedin.com/in/dr-sabrina-skorski-54534683 http://sportmedizin-saarbruecken.de/en/staff/dr-sabrina-skorski-phd https://twitter.com/brina1812 https://www.researchgate.net/profile/Sabrina_Skorski     Music Credit: Panthurr https://open.spotify.com/artist/2NZPNX4jXljA8MsUTrrgNq  https://instagram.com/spencer.panthurr  https://soundcloud.com/panthurr   Thanks for listening and we would love for you to subscribe so you don't miss any episodes!     Support the show: https://www.patreon.com/trainsmarterwithsciencepodcast See omnystudio.com/listener for privacy information.

Dr. Uri Tabori is a Staff Physician in the Division of Haematology/Oncology, Senior Scientist in the Genetics & Genome Biology program, and Principal Investigator of The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children (SickKids). In addition, Uri is a Professor in Paediatrics and Associate Professor in the Institute of Medical Sciences at the University of Toronto. Uri works as a physician treating kids with cancer, particularly brain tumors. Through his research, he is working to identify drugs and make new discoveries that may cure cancers or improve patients’ lives. When he’s not hard at work in the lab or clinic, Uri enjoys spending time with his family, watching American football, and exploring the wilderness of Canada. In particular, he is fond of canoeing and canoe camping with his family. He received his MD from the Hadassah School of Medicine of Hebrew University in Israel. Afterwards, he completed a Rotating Internship and his Residency in Pediatrics at the Sorasky Medical Center in Israel. Next, Uri accepted a Fellowship in Pediatric Hematology and Oncology at the Sheba Medical Center in Israel. He served as a Staff Physician in Pediatric Hematology and Oncology at The Sheba Medical Center for about a year before accepting a Research and Clinical Fellowship at The Hospital for Sick Children in Canada SickKids where he remains today. Over the course of his career, Uri has received numerous awards and honors, including the Early Researcher Award from the Ontario Ministry of Development and Innovation, the New Investigator Award from the Canadian Institute of Health Research, the Junior Physician Research Award from the University of Toronto Department of Pediatrics, The New Investigator Award from the Terry Fox Foundation, A Eureka! new investigator award from the International Course of Translational Medicine, A Merit Award from the American Society of Clinical Oncology Annual Meeting, and The Young Investigator Award from the Canadian Neuro-Oncology Society. In our interview, Uri shares more about his life, science, and clinical care.

I’m surprised by how much I didn’t know about sleep. I mean, I’ve done it a lot, sure. I for sure have earned my 10,000 hours – I’m should be a sleep expert! So far from the truth. Yeah, I’ll invest 1/3 of my life sleeping, but it’s insane to me that I’ve learned very little about the subject. Not too long ago, I heard about LeBron James secret to high-performance is getting GREAT sleep. Not more free throws. Not more affirmations. Not better coaching. It’s sleep. I use to view sleep as the thing I did when I wasn’t being productive, but now… I know that sleep is my key to productivity. Arguably, by body is being super productive while I’m in la-la land. It’s working through the night to repair, strengthen and build – so I can rock it out the next day. I believe that life is about charging hard. But I used to see that as something I did during the day. Now I know, it’s about charging hard during the day and allowing my body to charge “the batteries” at night. I’ve been tracking my sleep with my Oura ring, and each day playing close attention to what’s helping (or hurting) my sleep cycles. Lately, I’ve been feeling SOOOO much better. Let me back up for a minute. Why did I start putting so much focus on sleep? Last year, some blood work indicated a few areas where my body was breaking down. My iron was low, and hemoglobin counts were off. My doctor said, “You might have some type of internal bleed.” WTF! I was taken back by the news. I immediately began a quest to learn more about how my body heals itself – which quickly leads you to the sleep topic. There is so much info out there, but all roads seem to point back to getting a great night sleep being one of the most important elements to ultimate health. Over the past several months, I’ve been watching videos about sleep – anything from how to fall asleep, the importance of sleep quality, the difference between REM and deep sleep, etc. In my research, I found Dr. Matt Carter’s TEDx talk and knew we needed to chat further. Hence this show. A bit more about Matt. At Williams College, he is an Associate Professor of Biology where his lab studies how the brain regulates food intake and sleep. His research is funded by grants from the National Institutes of Health and the National Science Foundation. He received his Ph.D. in Neuroscience from Stanford University. He received the Nelson Bushnell Award for Excellence in Teaching and Writing from Williams College, the Walter Gores Award for Excellence in Teaching from Stanford University and the Young Investigator Award from the Sleep Research Society. He lives in Williamstown with his wife and two children. Enjoy the show fellas!   Join The Brotherhood: FrontRowDads.com/facebook Leave a Review: http://frontrowdads.com/review Website: FrontRowDads.com

In today’s episode, John returns to his conversation with renowned cancer researcher Dr. David S. Hong. Dr. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong has published more than 270 papers in leading academic journals. Topics include: Go/No-go decisions in clinical trials. Interchangeability of oncology drugs and biosimilars. Rising drug prices and declining trust in pharmaceutical companies. Health care delivery in the United States. Speaker Bios Dr. David S. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong received a bachelor’s degree in biology from Yale University and a medical degree from Albert Einstein College of Medicine. He then completed an internship and residency at Thomas Jefferson University Hospital and a medical oncology fellowship at MD Anderson, during which time he was appointed chief medical oncology fellow. In 2005, he joined MD Anderson’s faculty. Dr. Hong is the recipient of the 2004 Young Investigator Award from the American Society of Clinical Oncology, the Jesse H. Jones Fellowship in Cancer Education, MD Anderson’s Best Boss Award, the Irwin H. Krakoff Award for Excellence in Clinical Research, the Gerald P. Bodey Award for Excellence in Education and a research training fellowship from Howard Hughes Medical Institute. He has published more than 270 articles in prestigious journals. John Marchica is a veteran health care strategist and CEO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University, and is an active member of the American College of Healthcare Executives. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Yes I know I probably ruffled some feathers but to those who got upset, I say how can you help them see if you refuse to talk to them? And it seems everyone, has been trying to get this interview but I do my bet to Lead with Love and be nonconfrontational and respectful which has led to me be able to actually speak cordially with Paul on many occasions. Folks be the change you want to see is all I can say. I will never Lose hope that Paul will see the truth along with the many others I am trying to wake up. Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. SEE FULL BIO ON FACEBOOK EVENT wouldn't fit lol

In today’s episode, John has a fascinating conversation with renowned cancer researcher Dr. David S. Hong. Dr. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong has published more than 270 papers in leading academic journals. Topics include: The rise of immunotherapy and the Golden Age of cancer treatment. The role of clinical pathways and personalized medicine in improving patient care. Industry-researcher collaborations and investments in clinical trials. How physicians balance research with providing clinical care. Speaker Bios Dr. David S. Hong is deputy chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He also serves as associate vice president for Clinical Research and clinical medical director of the Clinical Center for Targeted Therapy. Dr. Hong received a bachelor’s degree in biology from Yale University and a medical degree from Albert Einstein College of Medicine. He then completed an internship and residency at Thomas Jefferson University Hospital and a medical oncology fellowship at MD Anderson, during which time he was appointed chief medical oncology fellow. In 2005, he joined MD Anderson’s faculty. Dr. Hong is the recipient of the 2004 Young Investigator Award from the American Society of Clinical Oncology, the Jesse H. Jones Fellowship in Cancer Education, MD Anderson’s Best Boss Award, the Irwin H. Krakoff Award for Excellence in Clinical Research, the Gerald P. Bodey Award for Excellence in Education and a research training fellowship from Howard Hughes Medical Institute. He has published more than 270 articles in prestigious journals. John Marchica is a veteran health care strategist and CEO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University, and is an active member of the American College of Healthcare Executives. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Dr. Kimberly Blackwell is Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology. In addition, Kim is Co-Founder of Cereius, a company that aims to improve the lives and survival of patients with solid tumor brain metastasis by using personalized and highly targeted radiotherapy. After 25 years of treating patients and conducting breast cancer research, Kim recently left her position in academic medicine to focus her efforts on getting new drugs to patients facing cancer. Kim’s hobbies include spending time with her family, watching her son’s baseball games, practicing yoga, meditating, skiing, and horseback riding. Kim received her bachelor’s degree in bioethics from Duke University and her M.D. from Mayo Clinic Medical School. Afterwards, she completed an internship and residency in internal medicine, as well as a fellowship in hematology/oncology at Duke University Medical School. Prior to accepting her position at Lilly, Kim was a faculty member at Duke University Medical Center. Kim has received numerous awards and honors throughout her career, including the Duke University Distinguished Alumni Award, the Young Investigator Award in Breast Cancer from the National Cancer Institute Specialized Program of Research Excellence, and the Joseph Greenfield Award for Mentorship of Clinical Research. She was also recognized as one of TIME Magazine's 100 Most Influential People in the World in 2013. In our interview Kim shares more about her life and science.

Our guest today Dr. Stuart Phillips, a professor of kinesiology at McMaster University in Ontario, Canada, who is best known for his research into muscle health and the benefits of dietary protein. Stu is the director of the McMaster Physical Activity Centre of Excellence, a state-of-the-art exercise research and training center. It is devoted to studying and improving the health and well-being of older adults as well as people with chronic diseases and disabilities. In addition to his work in the kinesiology department at McMaster, Stu is adjunct professor in the university’s School of Medicine. He is a fellow of the American College of Sports Medicine and the American College of Nutrition. He received the New Investigator Award from the Canadian Institutes for Health Research, the Ontario Premier's Research Excellence Award, and the Young Investigator Award from Canadian Society for Exercise Physiology.  In today’s interview we discuss:  [00:08:19] Dawn introduces the importance of dietary protein and its role in muscle health, and tissue regeneration more generally, which makes it one of the only macro nutrients we need on a daily basis. [00:10:59] A recent study (2017) showed that whole eggs promoted a greater amount of muscle protein synthesis than egg whites, suggesting that there may be benefits to the extra nutrients found in the egg yolk. [00:12:53] Why Stu believes the recommended daily allowance for protein is too low. [00:14:06] The differences between animal and plant-based protein. [00:16:31] The phenomenon of muscle synthesis (anabolism) and catabolism. [00:17:54] Highlights of the recent findings coming out of Kevin Tipton’s group which indicates that the dose-response relationship may depend on the amount of muscle tissue that was recruited during exercise, with the ingestion of 40 g protein further increasing muscle protein. [00:20:43]A 2013 paper from Stu’s group titled, “Dose-dependent responses of myofibrillar protein synthesis with beef ingestion are enhanced with resistance exercise in middle-aged men.” [00:27:52] Stu’s thoughts on the recommendation of pre-sleep protein feeding. [00:37:52] An overview of the Physical Activity Centre of Excellence, a state-of-the-art, exercise research and training lab at McMaster. [00:43:37] The importance of maintaining healthy functional muscle mass and function as we move into middle and later life. [00:46:56] Stu’s paper,  “Muscle Disuse as a Pivotal Problem in Sarcopenia-Related Muscle Loss and Dysfunction.” [00:50:25] The need to add more protein to our diets as we get older, which is something that Dr. Valter Longo discussed on episode 64 of STEM-Talk. [00:56:24 How fasting affects muscle protein turnover, which were topics covered in episode 7 of STEM-Talk, an interview with Mark Mattson, and episode 79, which was an interview with Satchin Panda, author of the “The Circadian Code.” [00:57:32] Whether a ketogenic diet with sufficient protein would in any way be detrimental to muscle mass. [01:05:47] Stu’s thoughts on a study that was conducted on behalf of the American College of Sports Medicine that found supplementation with HMB failed to enhance body composition to a greater extent than a placebo. Show notes [0:02:51] Stu talks about being born in the UK but growing up in Canada. [00:03:09] Dawn asks about Stu’s passions for all kinds of sports as a kid. [00:03:27] Stu recalls his high school science teacher, who was responsible for getting him interested in biology and chemistry. [00:03:44] Dawn asks what led Stu to choose McMaster University after high school. [00:04:19] Ken brings up that Stu was captain of the Ruby team his senior year, and while it looked as though he was headed to a great season, things didn’t turn out as planned. He asks how that season led to Stu’s decision to focus on nutritional biochemistry. [00:05:16] Stu explains how he ended up at Waterloo University to...

Yes I know I probably ruffled some feathers but to those who got upset, I say how can you help them see if you refuse to talk to them? And it seems everyone, has been trying to get this interview but I do my bet to Lead with Love and be nonconfrontational and respectful which has led to me be able to actually speak cordially with Paul on many occasions. Folks be the change you want to see is all I can say. I will never Lose hope that Paul will see the truth along with the many others I am trying to wake up. Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, See Facebook for full Bi

I will be interviewing none other than Dr. Paul Offit. Yes I know I will ruffle many feathers but to those who get upset I say how can you help them see if you refuse to talk to them. And it seems everyone, has been trying to get this interview but I do my bet to Lead with Love and be nonconfrontational and respectful which has led to me be able to actually speak cordially with Paul on many occasions. Folks be the change you want to see is all I can say. I will never Lose hope that Paul will see the truth along with the many others I am trying to wake up.  Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. SEE FULL BIO ON FACEBOOK EVENT wouldn't fit lol

Most of us believe that we are unique and coherent individuals, but are we? The idea of a “Self” has existed ever since humans began to live in groups and become sociable. Those who embrace the self as an individual in the West, or a member of the group in the East, feel fulfilled and purposeful. This experience seems incredibly real, but a wealth of recent scientific evidence reveals that this notion of the independent, coherent self is an illusion – it is not what it seems. In this talk, Professor Bruce Hood reveals how the self emerges during childhood and how the architecture of the developing brain enables us to become social animals dependent on each other. You'll learn how the self is the product of our relationships and interactions with others, and it exists only in our brains. Prof Hood argues, however, that though the self is an illusion, it is one that humans cannot live without. Professor Bruce Hood is the Professor of Developmental Psychology in Society in the School of Experimental Psychology at the University of Bristol. He has been a research fellow at Cambridge University and University College London, a visiting scientist at MIT and a faculty professor at Harvard. He has been awarded an Alfred Sloan Fellowship in neuroscience, the Young Investigator Award from the International Society of Infancy Researchers, the Robert Fantz memorial award and voted to Fellowship status by the society of American Psychological Science. He is the founder of the world's largest expert speaker database Speakezee.org, and the bestselling author of ”Supersense”, ‘The Self Illusion”, and the ”Domesticated Brain.' His new book, “Possessed” is published by Allen Lane in 2019. Links: Get our latest psychology lectures emailed to your inbox: http://bit.ly/new-talks Check out our next event: http://theweekenduniversity.com/events/ Support this channel on Patreon: https://www.patreon.com/theweekenduniversity Follow Bruce on twitter: @profbrucehood Check out Bruce's books: https://amzn.to/2LPwuul For more information on Speakezee, please see: http://speakezee.org

This episode we have a conversation with Dr. Jonathan Barnes, PhD. He is a recipient of the 2017 Young Investigator Award from the CRF. The Barnes group is developing a universal ‘plug-and-play’ type of drug delivery system to fight cancer. Learn more about Jonathan Barnes: https://www.cancerresearchfdn.org/recipient/jonathan-barnes https://twitter.com/jonathancbarnes http://pages.wustl.edu/barnes About the Cancer Research Foundation: https://www.cancerresearchfdn.org Our mission is to raise funds to fund early-career cancer scientists and new directions in cancer science research with the goal of contributing to “Transformational Events” in the prevention, treatment and cure for cancer. Young Investigator Award: https://www.cancerresearchfdn.org/program/young-investigator-awards/ Connect with us: https://www.cancerresearchfdn.org/ https://www.instagram.com/cancerrf Donate to help support early-career cancer science: https://www.cancerresearchfdn.org/support/

Nature interviews the winner of this year's Eppendorf Young European Investigator Award, Andrea Ablasser.

Dr. Kurt Hankenson is a Professor of Orthopaedic Surgery at the University of Michigan Medical School. Kurt is a veterinarian and a scientist. His research focuses on developing new treatments to improve bone healing as well as to treat bone loss conditions like osteoporosis. Outside of research, Kurt enjoys running, spending time with his wife and son, eating good food, drinking West Coast IPAs, traveling, listening to music, and reading. He received his Doctor of Veterinary Medicine degree from the University of Illinois. Afterwards, Kurt practiced equine veterinary medicine for a few years before returning to graduate school for his MS in Basic Medical Sciences from the Purdue University School of Veterinary Medicine. Kurt went on to earn his PhD in Biochemistry from the University of Washington, and he remained at the University of Washington to conduct postdoctoral research before accepting a faculty position at the University of Michigan. Kurt then served on the faculty at the University of Pennsylvania School of Veterinary Medicine for 8 years, and there he held the inaugural Dean W. Richardson Chair for Equine Research. Kurt worked briefly as a faculty member at Michigan State University before returning to the University of Michigan last year. Over the course of his career, Kurt has been awarded numerous honors including the Young Investigator Award, a John Haddad Fellowship, and also the Fuller Albright Award, all from the American Society for Bone and Mineral Research. In our interview, Kurt shared some of his experiences in life and science.

Dr. Rodrigo Quian Quiroga is a Professor and Director of the Centre for Systems Neuroscience at the University of Leicester in the United Kingdom. He is also an author of the books Borges and Memory, Principles of Neural Coding, Imaging Brain Function with EEG, and the recently published book The Forgetting Machine. Rodrigo enjoys getting out of the lab to do different activities to give his mind a break from thinking about experiments. In particular, he enjoys hanging out with his wife and kids, playing sports, and practicing Judo. Rodrigo is interested in understanding how memory works and how the brain works in general. He conducts experiments to determine how the neurons in our brain make us see, feel, make decisions, and remember the things we experience and learn in our lives. The memory research in Rodrigo’s lab investigates how memories are formed, stored, consolidated, and forgotten. Rodrigo received his undergraduate training in physics from the University of Buenos Aires in Argentina and was awarded his PhD in Applied Mathematics from the University of Luebeck in Germany. He was a postdoctoral fellow at the Research Center Juelich in Germany and he received a Sloan Fellowship to conduct research at the California Institute of Technology. Rodrigo also worked briefly at RIKEN in Japan and at the University of Nijmegen in The Netherlands. Rodrigo has received numerous awards and honors including the Royal Society Wolfson Research Merit Award, a Young Investigator Award from the American Epilepsy Society, and Rodrigo was also named one of 10 UK RISE Leaders in Science and Engineering in 2014. Rodrigo spoke with us about his experiences his career, research, and life.

Dr. Audrey Dussutour is a National Center for Scientific Research (CNRS) Scientist at Paul Sabatier University in Toulouse, France. When she’s not in front of her computer screen for work, Audrey loves going out to the movies and watching DVDs from her extensive collection. Some of her favorite directors are John Cassavetes and David Lynch, and she gets into sci-fi films as well. Audrey studies animal behavior and collective intelligence in ant colonies and slime molds. In ant colonies, she examines how the ants regulate traffic to avoid traffic jams. By observing how they behave, she can create algorithms that may help alleviate our own traffic jams. In slime molds, Audrey investigates the different cognitive abilities they are able to display even though they don’t have brains. Audrey received a Masters Degrees in Ecology from Paul Sabatier University, a Masters Degree in Neurosciences and Ethology from the Free University of Brussels in Belgium, and a PhD in Animal Behavior working in laboratories from both of these universities. She next conducted postdoctoral research at Concordia University in Canada and at the University of Sydney in Australia. Audrey has received numerous awards and honors for her exceptional work, including the Adolphe Wetrems Award of the Belgian Royal Academy, the Young Investigator Award of the French Society for the Study of Animal Behavior, the Outstanding Paper Prize from the Journal of Experimental Biology, Laureate du Prix Le Monde de la Recherche, and the Young Researcher Prize from the French Society for the Study of Animal Behavior. Audrey joined us for an interview to talk about her experiences in life and science.